Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 66
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Short-term effect of air pollution on attention function in adolescents (ATENC!Ó), A randomized controlled trial in high schools in Barcelona, Spain

  • Gignac, Florence|||0000-0002-1613-3364
  • Barrera-Gómez, José|||0000-0002-2688-6036
  • Persavento, Cecilia|||0000-0003-4665-5945
  • Solé Martín, Caterina|||0000-0002-1542-1487
  • Tena Gallego, Èlia|||0000-0002-8313-1377
  • López-Vicente, Mónica|||0000-0002-5090-7538
  • Foraster, Maria|||0000-0003-4450-4123
  • Amato, Fulvio|||0000-0003-1546-9154
  • Alastuey, Andrés|||0000-0002-5453-5495
  • Querol Carceller, Xavier|||0000-0002-6549-9899
  • Llavador, Humberto|||0000-0003-4058-7486
  • Apesteguia, Jose|||0000-0003-0733-9595
  • Júlvez, Jordi|||0000-0003-0818-4003
  • Couso, Digna|||0000-0003-4253-5049
  • Sunyer Deu, Jordi|||0000-0002-2602-4110
  • Basagaña, X.|||0000-0002-8457-1489
Background: The recent evidence of the short-term impact of air pollution on youth cognitive functions is based primarily on observational studies. Objectives: We conducted a randomized controlled trial to assess whether purifying the air of the classrooms produced short-term changes in attention processes of adolescents. Methods: We recruited a total of 2,123 adolescents (13-16 years old) in 33 high schools in Barcelona metropolitan area (Spain). In each school, adolescents from each class were randomly split into two equal-sized groups and assigned to two different classrooms. A set of two air cleaner devices with the same appearance (one recirculating and filtrating the air and the other only recirculating the air) was used. Each one of the devices was placed at random at one of the two classrooms. Students were masked to intervention allocation and had to complete several computerized activities for 1.5 h, including an attention test (Flanker task) to be performed at baseline and at the end of the intervention. The response speed consistency, expressed as hit reaction time standard error (HRT-SE, in ms), was measured as the primary outcome. Analyses were conducted using conditional linear regressions with classroom as strata, adjusted for variables that may differ from one class to another such as temperature, humidity and carbon dioxide concentration. Results: Average levels of PM2.5 and black carbon throughout the 1.5 h of experiment were 89% and 87%, respectively, lower in the classrooms with air cleaner than in the control classrooms. No differences were found in the median of HRT-SE between classrooms with cleaned air and normal air (percent change: 1.37%, 95% confidence interval: -2.81%, 5.56%). Sensitivity analyses with secondary attention outcomes resulted in similar findings. Conclusions: Cleaning the air of a classroom to reduce exposure to air pollutants for 1.5 h did not have an impact on the attention function of adolescents. Still, in light of previous evidence suggesting an association between air pollution and attention, further experimental studies should explore other short-term timescales of exposure and age ranges.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity

  • Núñez-Manchón, Judith
  • Capó, Júlia
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Juanola, Eduard
  • Pesovic, Jovan
  • Mosqueira-Martín, Laura
  • González-Imaz, Klaudia
  • Maestre-Mora, P.
  • Odria, Renato|||0000-0002-3420-797X
  • Savic-Pavicevic, Dusanka
  • Vallejo-Illarramendi, Ainara
  • Mamchaoui, Kamel
  • Bigot, Anne|||0000-0003-0337-5425
  • Mouly, Vicent
  • Suelves, Mònica|||0000-0001-7095-5804
  • Nogales, Gisela|||0000-0002-7414-212X
Historically, cellular models have been used as a tool to study myotonic dystrophy type 1 (DM1) and the validation of therapies in said pathology. However, there is a need for in vitro models that represent the clinical heterogeneity observed in patients with DM1 that is lacking in classical models. In this study, we immortalized three DM1 muscle lines derived from patients with different DM1 subtypes and clinical backgrounds and characterized them at the genetic, epigenetic, and molecular levels. All three cell lines display DM1 hallmarks, such as the accumulation of RNA foci, MBNL1 sequestration, splicing alterations, and reduced fusion. In addition, alterations in early myogenic markers, myotube diameter and CTCF1 DNA methylation were also found in DM1 cells. Notably, the new lines show a high level of heterogeneity in both the size of the CTG expansion and the aforementioned molecular alterations. Importantly, these immortalized cells also responded to previously tested therapeutics. Altogether, our results show that these three human DM1 cellular models are suitable to study the pathophysiological heterogeneity of DM1 and to test future therapeutic options.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Association Between the Mediterranean Diet and Fatty Acids in Red Blood Cells of Spanish Adolescents

  • Ayala-Aldana, Nicolas|||0000-0002-3530-6734
  • Lafuente, David
  • Lázaro, Iolanda|||0000-0002-6172-9845
  • Pinar-Martí, Ariadna|||0000-0002-2602-3396
  • Manidis, Alexios
  • Bernardo-Castro, Sara|||0000-0001-8809-5101
  • Fernández-Barrés, Sílvia|||0000-0002-9977-2291
  • Healy, Darren|||0000-0002-0084-2289
  • Vrijheid, Martine|||0000-0002-7090-1758
  • Contreras Rodríguez, Oren|||0000-0001-8922-8084
  • Sala-Vila, Aleix|||0000-0002-5038-2794
  • Júlvez, Jordi|||0000-0003-0818-4003
Objective: The Mediterranean diet (MedDiet) is characterized by its emphasis on plant-based foods, olive oil, and fish products, and has been associated with providing relevant fatty acids (FAs) for adolescent physiology. This study aims to investigate the relationship between adherence to the MedDiet and the FA composition of red blood cell (RBC) membranes in an adolescent population. Methods: The current research examines the relationship between MedDiet adherence, assessed using the KIDMED questionnaire, and the composition of RBC membranes, specifically measuring 22 FAs in a cross-sectional analysis of adolescents from two cohorts (mean age = 14.55). Baseline data from 552 participants with complete dietary adherence and FA information were analyzed using multivariable regression models and principal component analysis (PCA) as confirmatory analysis. All regression models were adjusted by age, sex, body mass index, physical activity, maternal education and cohort enrollment. Results: Main results shown that "Good adherence" to the MedDiet was positively associated with omega-3 FAs, including eicosapentaenoic acid (β = 0.34; 95% CI: 0.17, 0.52; p -value < 0.001) and docosahexaenoic acid (β = 0.29; 95% CI: 0.11, 0.46; p -value = 0.001), and inversely associated with specific omega-6 FAs, such as arachidonic acid (β = -0.28; 95% CI: -0.46, -0.11; p -value = 0.002) and adrenic acid (β = -0.19; 95% CI: -0.30, -0.08; p -value < 0.001). PCA identified distinct FA patterns, with "Good adherence" to the MedDiet being associated with an increase in the omega-3 FAs pattern (β = 0.32; 95% CI: 0.14, 0.49; p -value < 0.001). These findings remained robust after multiple test comparisons. Conclusions: This study underscores the potential of the MedDiet to promote optimal RBC FA composition in healthy adolescents, characterized by high levels of omega-3 FAs and reduced levels of arachidonic acid and adrenic acid in RBC membranes.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Random Forest-Based Prediction of Stroke Outcome

  • Fernández-Lozano, Carlos
  • Hervella, Pablo
  • Mato-Abad, Virginia
  • Rodríguez-Yáñez, Manuel
  • Suárez-Garaboa, Sonia
  • López-Dequidt, Iria
  • Estany-Gestal, Ana
  • Sobrino, Tomás
  • Campos, Francisco
  • Castillo, José
  • Rodríguez-Yáñez, S.
  • Iglesias Rey, Ramón
[Abstract] We research into the clinical, biochemical and neuroimaging factors associated with the outcome of stroke patients to generate a predictive model using machine learning techniques for prediction of mortality and morbidity 3-months after admission. The dataset consisted of patients with ischemic stroke (IS) and non-traumatic intracerebral hemorrhage (ICH) admitted to Stroke Unit of a European Tertiary Hospital prospectively registered. We identified the main variables for machine learning Random Forest (RF), generating a predictive model that can estimate patient mortality/morbidity according to the following groups: (1) IS + ICH, (2) IS, and (3) ICH. A total of 6022 patients were included: 4922 (mean age 71.9 ± 13.8 years) with IS and 1100 (mean age 73.3 ± 13.1 years) with ICH. NIHSS at 24, 48 h and axillary temperature at admission were the most important variables to consider for evolution of patients at 3-months. IS + ICH group was the most stable for mortality prediction [0.904 ± 0.025 of area under the receiver operating characteristics curve (AUC)]. IS group presented similar results, although variability between experiments was slightly higher (0.909 ± 0.032 of AUC). ICH group was the one in which RF had more problems to make adequate predictions (0.9837 vs. 0.7104 of AUC). There were no major differences between IS and IS + ICH groups according to morbidity prediction (0.738 and 0.755 of AUC) but, after checking normality with a Shapiro Wilk test with the null hypothesis that the data follow a normal distribution, it was rejected with W = 0.93546 (p-value < 2.2e−16). Conditions required for a parametric test do not hold, and we performed a paired Wilcoxon Test assuming the null hypothesis that all the groups have the same performance. The null hypothesis was rejected with a value < 2.2e−16, so there are statistical differences between IS and ICH groups. In conclusion, machine learning algorithms RF can be effectively used in stroke patients for long-term outcome prediction of mortality and morbidity., This study was partially supported by grants from the Spanish Ministry of Science and Innovation (SAF2017-84267-R), Xunta de Galicia (Axencia Galega de Innovación (GAIN): IN607A2018/3), Instituto de Salud Carlos III (ISCIII) (PI17/00540, PI17/01103), Spanish Research Network on Cerebrovascular Diseases RETICS-INVICTUS PLUS (RD16/0019) and by the European Union FEDER program. T. Sobrino (CPII17/00027), F. Campos (CPII19/00020) are recipients of research contracts from the Miguel Servet Program (Instituto de Salud Carlos III). General Directorate of Culture, Education and University Management of Xunta de Galicia (ED431G/01,252 ED431D 2017/16), “Galician Network for Colorectal Cancer Research" (Ref. ED431D 2017/23), Competitive Reference Groups (ED431C 2018/49), Spanish Ministry of Economy and Competitiveness via funding of the unique installation BIOCAI (UNLC08-1E-002, UNLC13-13–3503), European Regional Development Funds (FEDER)., Xunta de Galicia; IN607A2018/3, Xunta de Galicia; ED431G/01,252, Xunta de Galicia; ED431D 2017/16
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

  • Lachiondo-Ortega, Sofía
  • Rejano-Gordillo, Claudia María
  • Simón, Jorge
  • Lopitz-Otsoa, Fernando
  • Delgado, Teresa C.
  • Mazan-Mamczarz, Krystyna
  • Goikoetxea-Usandizaga, Naroa
  • Zapata-Pavas, L. Estefanía
  • García-del Río, Ana
  • Guerra, Pietro
  • Peña-Sanfélix, Patricia
  • Hermán-Sánchez, Natalia
  • Al-Abdulla, Ruba
  • Fernández-Rodríguez, Carmen
  • Azkargorta, Mikel
  • Velázquez-Cruz, Alejandro
  • Guyon, Joris
  • Martín, César
  • Zalamea, Juan Diego
  • Egia-Mendikute, Leire
  • Sanz-Parra, Arantza
  • Serrano-Maciá, Marina
  • González-Recio, Irene
  • Gonzalez-López, Monika
  • Martínez-Cruz, Luis Alfonso
  • Pontisso, Patrizia
  • Aransay, Ana M.
  • Barrio, Rosa
  • Sutherland, James D.
  • Abrescia, Nicola G. A.
  • Elortza, Félix
  • Lujambio, Amaia
  • Banales, Jesús M.
  • Luque, Raúl M.
  • Gahete, Manuel D.
  • Palazón, Asís
  • Ávila, Matías A.
  • Marín, José J. G.
  • De, Supriyo
  • Daubon, Thomas
  • Diaz-Quintana, Antonio
  • Díaz-Moreno, Irene
  • Gorospe, Myriam
  • Rodríguez, Manuel S.
  • Martínez-Chantar, María Luz
© 2024 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., The posttranslational modification of proteins critically influences many biological processes and is a key mechanism that regulates the function of the RNA-binding protein Hu antigen R (HuR), a hub in liver cancer. Here, we show that HuR is SUMOylated in the tumor sections of patients with hepatocellular carcinoma in contrast to the surrounding tissue, as well as in human cell line and mouse models of the disease. SUMOylation of HuR promotes major cancer hallmarks, namely proliferation and invasion, whereas the absence of HuR SUMOylation results in a senescent phenotype with dysfunctional mitochondria and endoplasmic reticulum. Mechanistically, SUMOylation induces a structural rearrangement of the RNA recognition motifs that modulates HuR binding affinity to its target RNAs, further modifying the transcriptomic profile toward hepatic tumor progression. Overall, SUMOylation constitutes a mechanism of HuR regulation that could be potentially exploited as a therapeutic strategy for liver cancer., This work was supported by grants to M.L.M.-C. from Departamento de Industria del Gobierno Vasco, Spain; Ministerio de Ciencia e Innovación, Spain (grant no. PID2020-117116RB-I00); European Regional Development Fund (ERDF), EU; and CIBERehd, which is funded by Instituto de Salud Carlos III (ISCIII), Spain. M.L.M.-C. and J.S. received funding from Ministerio de Ciencia e Innovación (grant no. RTC2019-007125-1) and ISCIII (grant no. DTS20/00138). M.L.M.-C. and R.M.L. acknowledge Ministerio de Ciencia e Innovación (grant no. RED2022-134397-T). M.L.M.-C. and J.M.B. were awarded with a grant from Fundación la Caixa, Spain (grant no. HR17-00601). M.L.M.-C., J.M.B., M.A.A., and J.J.G.M. acknowledge financial support from Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Spain. M.S.R. recognizes funding from Fondo Sectorial de Investigación SRE - CONACYT, Mexico (grant no. 0280365); Horizon 2020 Research and Innovation Program funded under Marie Skłodowska-Curie Actions, EU (grant no. 765445); and REPÈRE and Programme de Prématuration from Région Occitanie, France. M.G., S.D., and K.M.-M. were supported by the National Institute on Aging (NIA), National Institutes of Health (NIH), US (grant no. Z01-AG000511-23). I.D.-M. is grateful for the grants received from Junta de Andalucía, Spain (grant no. BIO-198, US-1254317, P18-FR-3487, and P18-HO-4091); Ministerio de Ciencia, Innovación y Universidades, Spain (grant no. PGC2018-096049-BI00); and Fundación Ramón Areces, Spain. T.D. acknowledges Fondation ARC, France (grant no. 208084). J.J.G.M. was supported by Junta de Castilla y León, Spain (grant no. SA063P17); Fundación La Marató TV3, Spain (grant no. 201916-31); ISCIII (grant no. PI19/00819); CIBERehd; and ERDF (grant no. OLD-HEPAMARKER). M.A.A. recognizes Gobierno de Navarra, Spain (grant no. GºNa 42/21); Eurorregión Nueva Aquitania-Euskadi-Navarra, Spain; Ministerio de Ciencia e Innovación (grant no. PID2019-104878RB-I00); and CIBERehd. A.P. expresses gratitude to the European Research Council (ERC), EU (grant no. 804236) for their support. M.D.G. received financial support from Junta de Andalucía (grant no. PEMP-0036-2020 and BIO-0139); Ministerio de Universidades, Spain (grant no. FPU20/03957); ISCIII (grant no. PI20/01301), Fundación Sociedad Española de Endocrinología y Nutrición (FSEEN), Spain; CIBERehd; and CIBERobn, which is also funded by ISCIII. J.M.B. acknowledges Euskadi RIS3 (grant no. 2019222054, 2020333010, and 2021333003) and Elkartek programs from Gobierno Vasco (grant no. KK-2020/00008); ISCIII (grant no. PI18/01075, CPII19/00008, and PI21/00922); CIBERehd; PSC Support, UK; AMMF The Cholangiocarcinoma Charity, UK (grant no. EU/2019/AMMFt/001); Horizon 2020 Research and Innovation Program (grant no. 825510); ERDF; and PSC Partners Seeking a Cure, US. A.L. received financial support from the Damon Runyon-Rachleff Innovation Award, US (grant no. DR52-18) and the MERIT Award (R37) from the National Cancer Institute (NCI), NIH (grant no. R37CA230636). F.E. expresses his gratitude to ProteoRed from ISCIII (grant no. PT13/0001/0027) and CIBERehd. N.G.A.A. was funded by Ministerio de Ciencia, Innovación y Universidades (grant no. RTI2018-095700-B-I00). R.B. acknowledges financial support from Gobierno Vasco (grant no. IT1165-19); Ministerio de Economía, Industria y Competitividad, Spain (grant no. SAF2017-90900-REDT); Ministerio de Economía, Industria y Competitividad, ERDF (grant no. BFU2017-84653-P); Ministerio de Ciencia e Innovación (grant no. PID2020-114178GB-I00); and Horizon 2020 funded under Marie Skłodowska-Curie Actions (grant no. 765445-EU). A.M.A. acknowledges CIBERehd. L.A.M.-C. obtained grants from Ministerio de Economía y Competitividad (grant no. CSD2008-00005); Ministerio de Economía, Industria y Competitividad (grant no. BFU2016-77408-R); ISCIII; and EJP RD, EU (grant no. EJPRD19-040). I.G.-R. was supported by Ministerio de Economía, Industria y Competitividad (grant no. BES-2017-080435 ). M.S.-M. is grateful to the AECC, Sede de Bizkaia, Spain for the financial support. J.D.Z. was awarded with a grant from Ministerio de Economía, Industria y Competitividad (grant no. SEV-2016-0644-18-2). C.M. acknowledges Gobierno Vasco (grant no. IT-1264-19) and Ministerio de Ciencia e Innovación (grant no. PID2022-136788OB-I00). A.V.-C. was supported by Ministerio de Educación, Cultura y Deporte, Spain (grant no. FPU016/01513). C.F.-R. thanks Tekniker, Spain and CIC bioGUNE, Spain for financial support. A.G.-d.R. was funded by Bikaintek program from Gobierno Vasco (grant no. 48-AF-W1-2019-00012). N.G.-U. obtained a grant from Gobierno Vasco. T.C.D. expresses gratitude to AECC. J.S. received financial support from CIBERehd. C.M.R.-G. was supported by Ayudas a la Recualificación Margarita Salas from Universidad de Extremadura, Ministerio de Universidades financed by NextGenerationEU., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Subgrouping a large U.S. sample of patients with fibromyalgia using the fibromyalgia impact questionnaire-revised

  • Pérez-Aranda, A.
  • Feliu-Soler, A.
  • Mist, S.D.
  • Jones, K.D.
  • López del Hoyo, Y.
  • Oliván-Arévalo, R.
  • Kratz, A.
  • Williams, D.A.
  • Luciano, J.V.
Fibromyalgia (FM) is a heterogeneous and complex syndrome; different studies have tried to describe subgroups of FM patients, and a 4-cluster classification based on the Fibromyalgia Impact Questionnaire-Revised (FIQR) has been recently validated. This study aims to cross-validate this classification in a large US sample of FM patients. A pooled sample of 6280 patients was used. First, we computed a hierarchical cluster analysis (HCA) using FIQR scores at item level. Then, a latent profile analysis (LPA) served to confirm the accuracy of the taxonomy. Additionally, a cluster calculator was developed to estimate the predicted subgroup using an ordinal regression analysis. Self-reported clinical measures were used to examine the external validity of the subgroups in part of the sample. The HCA yielded a 4-subgroup distribution, which was confirmed by the LPA. Each cluster represented a different level of severity: “Mild–moderate”, “moderate”, “moderate–severe”, and “severe”. Significant differences between clusters were observed in most of the clinical measures (e.g., fatigue, sleep problems, anxiety). Interestingly, lower levels of education were associated with higher FM severity. This study corroborates a 4-cluster distribution based on FIQR scores to classify US adults with FM. The classification may have relevant clinical implications for diagnosis and treatment response.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Impact of mindfulness and self-compassion on anxiety and depression: The mediating role of resilience [Impacto del mindfulness y de la autocompasión en la ansiedad y la depresión: rol mediador de la resiliencia]

  • Pérez-Aranda, A.
  • García-Campayo, J.
  • Gude, F.
  • Luciano, J.V.
  • Feliu-Soler, A.
  • González-Quintela, A.
  • López-del-Hoyo, Y.
  • Montero-Marin, J.
Background/Objective ‘Third-wave’ psychotherapies have shown effectiveness for treating psychopathological symptoms such as anxiety and depression. There is burgeoning interest in examining how these therapies’ core constructs produce their therapeutic benefits. This study explores the hypothetical mediating effect of resilience in the impact of mindfulness and self-compassion on anxiety and depressive symptoms. Method: Cross-sectional study design. The sample consisted of 860 Spanish general population participants. The measures included the Mindful Attention Awareness Scale (MAAS), the Self-Compassion Scale (SCS-12), the Connor-Davidson Resilience Scale (CD-RISC) and the Goldberg Anxiety and Depression Scale (GADS). Bivariate correlations were calculated, and path analysis models were performed. Results: Significant correlations were found between the study variables, always in the expected direction (all p values <.001). The path analysis models showed significant direct effects of mindfulness and self-compassion on anxiety and depression symptoms, but the only significant indirect effects through resilience were found on depression (MAAS: ß = -.05, 95% CI = -.11 to -.02; SCS-12: ß = -.06, 95% CI = -.33 to -.07). Conclusions: Resilience might partially mediate the effect of mindfulness and self-compassion on depression, but not on anxiety.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder

  • Moreno‑Alcázar, Ana
  • Ribases Haro, Marta
  • Sanchez Mora, Cristina P
  • Palomar Martínez, Gloria
  • Bosch Munso, Rosa M
  • Casas Brugué, Miquel
  • Ramos-Quiroga, Josep Antoni
TDAH; Genotipatge; Imatges per ressonància magnètica, TDAH; Genotipado; Imagen de resonancia magnética, ADHD; Genotyping; Magnetic resonance imaging, Previous studies have shown that the gene encoding the adhesion G protein-coupled receptor L3 (ADGRL3; formerly latrophilin 3, LPHN3) is associated with Attention-Deficit/Hyperactivity Disorder (ADHD). Conversely, no studies have investigated the anatomical or functional brain substrates of ADGRL3 risk variants. We examined here whether individuals with different ADGRL3 haplotypes, including both patients with ADHD and healthy controls, showed differences in brain anatomy and function. We recruited and genotyped adult patients with combined type ADHD and healthy controls to achieve a sample balanced for age, sex, premorbid IQ, and three ADGRL3 haplotype groups (risk, protective, and others). The final sample (n = 128) underwent structural and functional brain imaging (voxel-based morphometry and n-back working memory fMRI). We analyzed the brain structural and functional effects of ADHD, haplotypes, and their interaction, covarying for age, sex, and medication. Individuals (patients or controls) with the protective haplotype showed strong, widespread hypo-activation in the frontal cortex extending to inferior temporal and fusiform gyri. Individuals (patients or controls) with the risk haplotype also showed hypo-activation, more focused in the right temporal cortex. Patients showed parietal hyper-activation. Disorder-haplotype interactions, as well as structural findings, were not statistically significant. To sum up, both protective and risk ADGRL3 haplotypes are associated with substantial brain hypo-activation during working memory tasks, stressing this gene’s relevance in cognitive brain function. Conversely, we did not find brain effects of the interactions between adult ADHD and ADGRL3 haplotypes., This work was supported by several grants from the Plan Nacional de I+D+i and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund (FEDER): Research Project Grant (PI11/01629, PI11/01766, PI16/01505, PI17/00289, PI18/01788, PI19/00394, PI19/00721, and PI19/01224), Miguel Servet Research Contracts (CP09/00119 and CPII15/00023 to MR, CP10/00596 to EP-C and CP14/00041 and CPII19/00009 to JR), Sara Borrell contract (CD15/00199 to CSM), PFIS contract (FI20/00047 to LF), mobility grant (MV16/00039 to CSM), Pla Estratègic de Recerca i Innovació en Salut (PERIS); Generalitat de Catalunya (MENTAL-Cat; SLT006/17/287) and the Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR, Catalonian Government (2009SGR211 and 2017SGR1461). The funding organizations played no role in the study design, data collection and analysis, or manuscript approval.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours

  • Groelly, Florian
  • Porru, Manuela
  • Zimmer, Jutta
  • Benainous, Hugo
  • De Visser, Yanti
  • Kosova, Anastasiya
  • Serra Elizalde, Violeta
BRCA2; DNA damage responses; Pyridostatin, BRCA2; Respostes al dany de l'ADN; Piridostatina, BRCA2; Respuestas al daño del ADN; Piridotatina, The cells with compromised BRCA1 or BRCA2 (BRCA1/2) function accumulate stalled replication forks, which leads to replication-associated DNA damage and genomic instability, a signature of BRCA1/2-mutated tumours. Targeted therapies against BRCA1/2-mutated tumours exploit this vulnerability by introducing additional DNA lesions. Because homologous recombination (HR) repair is abrogated in the absence of BRCA1 or BRCA2, these lesions are specifically lethal to tumour cells, but not to the healthy tissue. Ligands that bind and stabilise G-quadruplexes (G4s) have recently emerged as a class of compounds that selectively eliminate the cells and tumours lacking BRCA1 or BRCA2. Pyridostatin is a small molecule that binds G4s and is specifically toxic to BRCA1/2-deficient cells in vitro. However, its in vivo potential has not yet been evaluated. Here, we demonstrate that pyridostatin exhibits a high specific activity against BRCA1/2-deficient tumours, including patient-derived xenograft tumours that have acquired PARP inhibitor (PARPi) resistance. Mechanistically, we demonstrate that pyridostatin disrupts replication leading to DNA double-stranded breaks (DSBs) that can be repaired in the absence of BRCA1/2 by canonical non-homologous end joining (C-NHEJ). Consistent with this, chemical inhibitors of DNA-PKcs, a core component of C-NHEJ kinase activity, act synergistically with pyridostatin in eliminating BRCA1/2-deficient cells and tumours. Furthermore, we demonstrate that pyridostatin triggers cGAS/STING-dependent innate immune responses when BRCA1 or BRCA2 is abrogated. Paclitaxel, a drug routinely used in cancer chemotherapy, potentiates the in vivo toxicity of pyridostatin. Overall, our results demonstrate that pyridostatin is a compound suitable for further therapeutic development, alone or in combination with paclitaxel and DNA-PKcs inhibitors, for the benefit of cancer patients carrying BRCA1/2 mutations., Research in A.B. laboratory is supported by grants of Italian Association for Cancer Research (AIRC # 21579), Ministry of Health (CO 2019-12369662) and from IRCCS-Regina Elena Cancer Institute. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 722729 (F.J.G.). Research in M.T. laboratory is supported by Cancer Research UK (DRCPGM\100001), Medical Research Council and University of Oxford. A.R. received support from the UK Medical Research Council grant MC_PC_12006. V.S. received support from Instituto de Salud Carlos III (CPII19/00033, PI17/01080), GHD pink and the FERO Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

  • Yndestad, Synnøve
  • Engebrethsen, Christina
  • Nikolaienko, Oleksii
  • Vintermyr, Olav Karsten
  • Lillestøl, Reidun
  • Llop-Guevara, Alba
  • Herencia Ropero, Andrea
  • Serra, Violeta
Homologous recombination; Primary breast cancer, Recombinació homòloga; Càncer de mama primari, Recombinación homóloga; Cáncer de mama primario, PURPOSE Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to assess the potential for PARPi in a wider group of patients with breast cancer. METHODS HRD status was established using targeted gene panel sequencing (360 genes) and BRCA1 methylation analysis of pretreatment biopsies from 201 patients with primary breast cancer in the phase II PETREMAC trial (ClinicalTrials.gov identifier: NCT02624973). HRD was defined as mutations in BRCA1, BRCA2, BRIP1, BARD1, or PALB2 and/or promoter methylation of BRCA1 (strict definition; HRD-S). In secondary analyses, a wider definition (HRD-W) was used, examining mutations in 20 additional genes. Furthermore, tumor BRCAness (multiplex ligation-dependent probe amplification), PAM50 subtyping, RAD51 nuclear foci to test functional HRD, tumor-infiltrating lymphocyte (TIL), and PD-L1 analyses were performed. RESULTS HRD-S was present in 5% of non-TNBC cases (n = 9 of 169), contrasting 47% of the TNBC tumors (n = 15 of 32). HRD-W was observed in 23% of non-TNBC (n = 39 of 169) and 59% of TNBC cases (n = 19 of 32). Of 58 non-TNBC and 30 TNBC biopsies examined for RAD51 foci, 4 of 4 (100%) non-TNBC and 13 of 14 (93%) TNBC cases classified as HRD-S had RAD51 low scores. In contrast, 4 of 17 (24%) non-TNBC and 15 of 19 (79%) TNBC biopsies classified as HRD-W exhibited RAD51 low scores. Of nine non-TNBC tumors with HRD-S status, only one had a basal-like PAM50 signature. There was a high concordance between HRD-S and either BRCAness, high TIL density, or high PD-L1 expression (each P < .001). CONCLUSION The prevalence of HRD in non-TNBC suggests that therapy targeting HRD should be evaluated in a wider breast cancer patient population. Strict HRD criteria should be implemented to increase diagnostic precision with respect to functional HRD., Supported by unrestricted grants from The K.G. Jebsen Foundation [SKGJ-MED-020 to H.P.E., S.K., P.E.L.], Helse Vest [912008 to P.E.L.], The Norwegian Research Council [273354 to P.E.L.] and The Norwegian Cancer Society [190281-2017 to S.K., 190275-2017 to P.E.L.]. Research funding was provided by Grieg Foundation (to H.P.E. and T.A.), Helse Vest [912252; Clinical researcher fellowship to H.P.E.], Generalitat de Catalunya [PERIS, SLT017/20/000081 to A.H.R.], “la Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 [LCF/TR/CC19/52470003 to A.L.G.], Asociación Española Contra el Cáncer [AECC, INVES20095LLOP to A.L.G.], Generalitat de Catalunya (PERIS Fellowship SLT002/16/00477 to A.L.G.) ERA PerMed [2019-215 to V.S.] and Miguel Servet fellowship (CPII19/00033 to V.S.). Additional funding and study medication was provided by Illumina [grant number 9529854], Pfizer [WI206347] and AstraZeneca [ESR-14-10077] to H.P.E., S.K., P.E.L.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts

  • Òdena, Andreu
  • Casals, Eloi
  • Molina, Cristina
  • Coşkun, Meriç
  • Guzman Torres, Marta
  • Brasó Maristany, Fara
  • García-Galea, Eduardo
  • Herencia Ropero, Andrea
  • Domènech Garcia, Heura
  • Rodríguez, Olga
  • Grueso, Judit
  • Dienstmann, Rodrigo
  • Oliveira, Mafalda
  • Monserrat, Laia
  • Serra, Violeta
Patritumab deruxtecan; Xenografts; Breast cancer, Patritumab deruxtecan; Xenoinjertos; Cáncer de mama, Patritumab deruxtecan; Xenoempelt; Càncer de mama, Novel antibody-drug conjugates (ADCs) have shown potent antitumor activity across multiple cancer types. However, the key determinants of therapeutic response remain under investigation. In this study, we aimed to identify potential determinants of long-term response to patritumab deruxtecan (HER3-DXd; MK-1022), a HER3-directed ADC linked to a potent topoisomerase I inhibitor (TOP1i) payload, using a cohort of thirty-one breast cancer (BC) patient-derived xenograft (PDX) models. Fourteen out of 31 (45%) PDXs exhibited a profound and sustained response to HER3-DXd. Basal-like PAM50 intrinsic subtype, limited prior exposure to chemotherapy and intrinsic sensitivity to the TOP1i irinotecan were associated with long-term response. Additionally, HER3-DXd showed sustained activity in BRCA1/BRCA2-mutated PARPi-resistant PDX models. Long-term responders exhibited persistent DNA damage and lacked early transcriptional activation of the G2/M cell cycle checkpoint that allow for DNA repair and RNA-DNA hybrid (R-loop) resolution, in parallel resulting in immune pathways transcriptional activation. Notably, characteristics linked to long-term response were primarily associated with the TOP1i payload activity., VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA program from the Generalitat de Catalunya for their support on this research. This study was supported by the Asociación Española Cáncer de Mama Metastásico (AECMM) (III Metapremio M. Chiara Giorgetti 2021) and by the Catalan Agency AGAUR-FEDER (2021 SGR 01510 to V. Serra). V. Serra received funds from the Instituto de Salud Carlos III (ISCIII), and co-funded by the European Union (PI20/00892 and CPII19/00033). The FERO Foundation and GHD also provided support to V. Serra. A. Òdena and L. Monserrat received fellowships from the Agency for Management of University and Research Grants (2022 FI_B 00664 and AGAUR 2019 FI_B 01199, respectively). F. Brasó-Maristany received funding from Fundación científica AECC Ayudas Investigador AECC 2021 (INVES21943BRAS) and Fundación Contigo (HIMALAIA). A. Herencia-Ropero received funding from Generalitat de Catalunya (PERIS SLT017/20/000081). F. Pedretti received a fellowship from La Caixa Foundation (ID 100010434) (LCF/BQ/DI19/11730051). H. Domènech received a Severo Ochoa fellowship from the Spanish Ministry of Science and Innovation (PRE2021-099087). A. Esteve-Codina. reports that Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. S. Chandarlapaty is supported by MSK Cancer Center Support Grant P30 CA008748 and the BCRF. A. Prat received funding from the Breast Cancer Research Foundation (BCRF-22-198, BCRF-23-198, BCRF-24-198), Beca Marta Santamaría, Fundación CRIS contra el Cancer (PR_EX_2021-14), Agència de Gestó d’Ajuts Universitaris I de Recerca (2021 SGR 01156), Fundación Fero (ONCOXXI21), Asociación Cáncer de Mama Metastásico (IV Premios M. Chiara Giorgetti), PI22/01017: funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and RESCUER: funded by European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912. We would like to acknowledge Daiichi Sankyo and Merck Inc. for providing the HER3-DXd and the IgG-DXd and Astrazeneca Inc. for supplying the olaparib used in the study. Finally, we would like to acknowledge the patients who donate samples for the generation of the PDX models used in this study.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

  • Ring, Alistair
  • Kilburn, Lucy
  • Pearson, Alex
  • Moretti, Laura
  • Afshari-Mehr, Angelica
  • Wardley, Andrew
  • Llop Guevara, Alba
  • Serra, Violeta
Olaparib; Ceralasertib; Triple-negative advanced breast cancer, Olaparib; Ceralasertib; Càncer de mama avançat triple negatiu, Olaparib; Ceralasertib; Cáncer de mama avanzado triple negativo, Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous replication stress and thereby increase sensitivity to inhibitors of ataxia telangiectasia and Rad3-related (ATR) protein. This phase II study examined the activity of the combination of PARP inhibitor, olaparib, and ATR inhibitor, ceralasertib (AZD6738), in patients with advanced TNBC. Patients and Methods: Patients with TNBC on most recent biopsy who had received 1 or 2 lines of chemotherapy for advanced disease or had relapsed within 12 months of (neo)adjuvant chemotherapy were eligible. Treatment was olaparib 300 mg twice a day continuously and celarasertib 160 mg on days 1–7 on a 28-day cycle until disease progression. The primary endpoint was confirmed objective response rate (ORR). Tissue and plasma biomarker analyses were preplanned to identify predictors of response. Results: 70 evaluable patients were enrolled. Germline BRCA1/2 mutations were present in 10 (14%) patients and 3 (4%) patients had somatic BRCA mutations. The confirmed ORR was 12/70; 17.1% (95% confidence interval, 10.4–25.5). Responses were observed in patients without germline or somatic BRCA1/2 mutations, including patients with mutations in other homologous recombination repair genes and tumors with functional homologous recombination deficiency by RAD51 foci. Conclusions: The response rate to olaparib and ceralasertib did not meet prespecified criteria for activity in the overall evaluable population, but responses were observed in patients who would not be expected to respond to olaparib monotherapy., This research was funded by the Stand Up to Cancer Campaign for Cancer Research UK (CRUK/15/010, C30746/A19505; to S. Martin, H. Johnson, L. Moretti) with additional support from AstraZeneca, Guardant Health, Bio-Rad and Asociación Española Contra el Cáncer (AECC, INVES20095LLOP; to A. Llop-Guevara). The ICR Clinical Trials and Statistics Unit is supported by the Cancer Research UK core programme grant (C1491/A25351; to L.S. Kilburn). This study represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, London, UK. In addition, plasmaMATCH is supported by the NIHR Manchester Clinical Research Facility at the Christie Hospital, Manchester, UK, the NIHR UCLH Clinical Research Facility at University College London Hospitals NHS Foundation Trust, London, UK, the Cancer Research UK Cambridge Centre, Cambridge Biomedical Research Centre (BRC-1215–20014) and Cambridge Experimental Cancer Medicine Centre, Cambridge, UK. The RAD51 analysis was supported with grants from the Spanish Association of Cancer Research and Instituto de Salud Carlos III (ERAPERMED2019–215, CPII19/00033, and INVES20095LLOP). plasmaMATCH is supported at participating sites in England by the NIHR Clinical Research Network, in Scotland by the Chief Scientist Office, and in Wales by Health and Care Research Wales.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

  • Carreira, Suzanne
  • Porta, Nuria
  • Arce-Gallego, Sara
  • Llop Guevara, Alba
  • Bianchini, Diletta
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Seed, George
Pròstata; PARP; Biomarcadors, Próstata; PARP; Biomarcadores, Prostate; PARP; biomarkers, PARP inhibitors are approved for treating advanced prostate cancers (APCs) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B Phase II clinical trial samples, evaluating whole exome and low-pass whole genome sequencing and immunohistochemical assays evaluating ATM and RAD51 foci (testing homologous recombination repair function). BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA deletion. Biallelic, but not mono-allelic, PALB2 deleterious alterations were associated with clinical benefit. In the ATM cohort, loss of ATM protein by immunohistochemistry associated with better outcome. RAD51 foci loss identified tumors with biallelic BRCA and PALB2 alteration while most ATM- and CDK12-altered APCs had higher RAD51 foci levels. Overall, APCs with homozygous BRCA2 deletion are exceptional responders; PALB2 biallelic loss and loss of ATM immunohistochemical expression associated with clinical benefit., TOPARP is an investigator-initiated trial; we are grateful for the support and funding from AstraZeneca, and for the study grants from Cancer Research UK (CRUK/11/029; C12540/A12829; C12540/A13230; C12540/A20447). ICR-CTSU also receives program grant funding from Cancer Research UK (Grant number: C1491/A15955, C1491/A25351). We acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence (CEO13_2-002), the Prostate Cancer Foundation, and the UK Department of Health through an Experimental Cancer Medicine Centre (ECMC) grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Pasquale Rescigno was supported by a PCF Young Investigator Award 19YOUN19. The authors affiliated to VHIO acknowledge funding from “La Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 (LCF/TR/CC19/52470003), Fundacion FERO and Fundacion Cellex. J. Mateo, A. Llop-Guevara and V. Serra received grants from Fundacion Cientifica AECC (LABAE16020PORTT) and an ERAPERMED2019-215. J. Mateo gratefully acknowledges funding from the European Union’s Horizon 2020 research and innovation program (Marie Skłodowska-Curie grant 837900), Instituto de Salud Carlos III (Grant PI18/01384), Fundación AECC, CRIS Cancer Foundation and the US Department of Defense CDMRP (Impact Award PC170510P1). S. Arce-Gallego Research. Downloaded from cancerdiscovery.aacrjournals.org on July 1, 2021. © 2021 American Association for Cancer Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 27, 2021; DOI: 10.1158/2159-8290.CD-21-0007 3 and V. Serra were supported by Instituto de Salud Carlos III (FI19/00280, CPII19/00033).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test

  • Kramer, Claire
  • Yaniz-Galende, Elisa
  • Pellegrino, Benedetta
  • ter Haar, Natalja
  • Llop-Guevara, Alba
  • Herencia Ropero, Andrea
  • Serra, Violeta
Biomarker; High-hrade serous ovarian carcinoma; Homologous recombination deficiency, Biomarcador; Carcinoma de ovario seroso de alto grado; Deficiencia de recombinación homóloga, Biomarcador; Carcinoma d'ovari serós d'alt grau; Deficiència de recombinació homòloga, The RAD51 test is emerging as a promising biomarker for the assessment of functional homologous recombination deficiency (HRD). Yet, the robustness and reproducibility of the immunofluorescence-based RAD51 test, in different academic laboratories, have not been systematically investigated. Therefore, we tested the performance of the RAD51 assay in formalin-fixed paraffin-embedded (FFPE) high-grade serous ovarian carcinoma (HGSOC) samples in four European laboratories. Here, we confirm that subtle differences in staining procedures result in low variability of RAD51 and γH2AX scores. However, substantial variability in RAD51 scoring was observed in some samples, likely due to complicating technical and biological features, such as high RAD51 signal-to-noise ratio and RAD51 heterogeneity. These results support the need to identify and perform additional quality control steps and/or automating image analysis. Altogether, resolving technical issues should be a priority, as identifying tumours with functional HRD is urgently needed to guide the individual treatment of HGSOC patients. Follow-up studies are needed to define the key tissue quality requirements to assess HRD by RAD51 in FFPE tumour samples, as this test could help in guiding the individual treatment of HGSOC patients., This work was supported by the Dutch Cancer Society (KWF) (grant: 12995 to TB and MV) and by ERA PerMed (grant ERAPERMED2019-215 to VS). VS received funding from Instituto de Salud Carlos III (CPII19/00033). ALG received funding from Asociación Española Contra el Cáncer (AECC) (INVES20095LLOP) and AHR from Generalitat de Catalunya (PERIS SLT017/20/000081).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel
  • Palafox Sánchez, Marta
  • Scaltriti, Maurizio
  • Razavi, Pedram
  • Arribas López, Joaquin Vicente
  • Serra Elizalde, Violeta
  • Gris Oliver, Albert
  • Bellet Ezquerra, Meritxell
Biomarcadores de respuesta a fármacos; Redes de co-ocurrencia de conductores; Oncología de precisión, Biomarcadors de resposta a fàrmacs; Xarxes de co-ocurrència de conductors; Oncologia de precisió, Drug-response biomarkers; Driver co-occurrence networks; Precision oncology, Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients’ progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling., L.M. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the Generalitat de Catalunya (VEIS 001-P-001). V.S. is a recipient of a Miguel Servet grant from ISCIII (CPII19/00033) and receives funds from AGAUR (2017 SGR 540). The PDX program is supported by a GHD-Pink (FERO foundation) grant to V.S., A.G.-O. and M.P. received a FI-AGAUR and a Juan de la Cierva (MJCI-2015-25412) fellowship, respectively. M.S., P.R., and S.C. acknowledge the support of the NIH grants P30 CA008748, RO1CA190642, and the Breast Cancer Research Foundation. Additionally, P.R. receives funds from the Breast Cancer Alliance.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

  • Capoluongo, Ettore Domenico
  • Pellegrino, B.
  • Califano, D.
  • Beltrame, L.
  • Serra Elizalde, Violeta
  • Llop Guevara, Alba
  • Scambia, Giovanni
Molecular testing; Ovarian cancer, Proves moleculars; Càncer d'ovaris, Pruebas moleculares; Cáncer de ovarios, Background The detection of homologous recombination deficiency (HRD) can identify patients who are more responsive to platinum and poly ADP ribose polymerase inhibitors (PARPi). MyChoice CDx (Myriad) is the most used HRD test in ovarian cancer (OC). However, some limitations of commercial tests exist, because of the high rate of inconclusive results, costs, and the impossibility of evaluating functional resistance mechanisms. Patients and methods Two academic genomic tests and a functional assay, the RAD51 foci, were evaluated to detect HRD. One hundred patients with high-grade OC enrolled in the MITO16A/MaNGO-OV2 trial and treated with first-line therapy with carboplatin, paclitaxel, and bevacizumab were analyzed. Results The failure rate of the two genomic assays was 2%. The sensitivity in detecting HRD when compared with Myriad was 98.1% and 90.6%, respectively. The agreement rate with Myriad was 0.92 and 0.87, with a Cohen’s κ coefficient corresponding to 0.84 and 0.74, respectively. For the RAD51 foci assay, the failure rate was 30%. When the test was successful, discordant results for deficient and proficient tumors were observed, and additional HRD patients were identified compared to Myriad; sensitivity was 82.9%, agreement rate was 0.65, and Cohen’s κ coefficient was 0.18. The HRD detected by genomic assays and residual tumor at primary surgery and stage was correlated with progression-free survival at multivariate analysis. Conclusions Results suggest the feasibility of academic tests for assessing HRD status that show robust concordance with Myriad and correlation with clinical outcome. The contribution of the functional information related to the RAD51 foci test to the genomic data needs further investigation., This work was supported by funding from the AIRC [grant numbers IG 2016 – ID. 18921 and IG 2021 – ID. 25932 projects – P.I. SP and CO-2018-12367051 (Ministero della Salute) P.I SP]; Ricerca Corrente grant M2/7 from Ministero della Salute to DC, Ricerca Corrente from Ministero della Salute to SP. SM is supported by the Italian Association for Cancer Research [grant number IG-2017 n: IG19997]. MITO16A/MaNGO-OV2 trial was partially supported by Roche. AL is a recipient of a grant from the Asociación Española contra el Cáncer (AECC) [grant number INVES20095LLOP]. VS is a recipient of a grant from the Instituto de Salud Carlos III [grant number CPII19/00033] and a European grant for personalized medicine [grant number ERAPERMED 2019-215]. BP is a recipient of a grant from GOIRC. BP was supported by ESMO with a Clinical Translational Fellowship aid supported by Roche. Any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of ESMO or Roche. NC has received funding from AstraZeneca (to the institution). FP has received funding from Roche, AstraZeneca, Pfizer, Merck Sharp & Dome, Bayer, Incyte, Taiho Oncology, Janssen Cilag, Exelixis, Aileron, and Daiichi Sankyo (grants to the institution for clinical trial activities).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

  • Rodriguez, María Jimena
  • Perrone, María Cecilia
  • Riggio, Marina
  • Palafox Sánchez, Marta
  • Salinas, Valeria
  • Elia, Andres
  • Serra Elizalde, Violeta
Cancer; Cell biology, Càncer; Biologia cel·lular, Cáncer; Biología celular, Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, highlighting the need for novel therapeutic strategies to delay disease progression and improve patient survival. Here, we assessed the mechanisms of acquired resistance using T47D and MCF-7 tamoxifen- and palbociclib-resistant cell-line variants in culture and as xenografts, and patient-derived cells (PDCs) obtained from sensitive or resistant patient-derived xenografts (PDXs). In these models, we analyzed the effect of specific kinase inhibitors on survival, signaling and cellular aggressiveness. Our results revealed that mTOR inhibition is more effective than PI3K inhibition in overcoming resistance, irrespective of PIK3CA mutation status, by decreasing cell proliferation and tumor growth, as well as reducing cell migration and stemness. Moreover, a combination of mTOR and CDK4/6 inhibitors may prevent pathway reactivation downstream of PI3K, interfering with the survival of resistant cells and consequent tumor escape. In conclusion, we highlight the benefits of incorporating mTOR inhibitors into the current therapy in ER + breast cancer. This alternative therapeutic strategy not only enhances the antitumor response but may also delay the emergence of resistance and tumor recurrence., This work was supported by CONICET, ANPCYT (Grants PICT2509 & PICT0345), Instituto Nacional del Cáncer (Grants 2016 & 2018), Fundación Williams, Fundación Bunge & Born (Oster Grant) (Argentina); Instituto de Salud Carlos III (Grants PI20/00892 & CPII19/0033), Ministerio de Economía y Competitividad (FJCI-2015-25412) (Spain).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

  • Shah, Jennifer
  • Pueschl, Dana
  • Wubbenhorst, Bradley
  • Fan, Mengyao
  • Pluta, John
  • D’Andrea, Kurt
  • Llop Guevara, Alba
  • Serra Elizalde, Violeta
  • Balmaña Gelpí, Judith
Breast cancer; Cancer genetics; RNA sequencing, Cáncer de mama; Genética del cáncer; Secuenciación de ARN, Càncer de mama; Genètica del càncer; Seqüenciació d'ARN, Recurrence is a major cause of death among BRCA1/2 mutation carriers with breast (BrCa) and ovarian cancers (OvCa). Herein we perform multi-omic sequencing on 67 paired primary and recurrent BrCa and OvCa from 27 BRCA1/2 mutation carriers to identify potential recurrence-specific drivers. PARP1 amplifications are identified in recurrences (False Discovery Rate q = 0.05), and PARP1 is significantly overexpressed across primary BrCa and recurrent BrCa and OvCa, independent of amplification status. RNA sequencing analysis finds two BRCA2 isoforms, BRCA2-201/Long and BRCA2-001/Short, respectively predicted to be sensitive and insensitive to nonsense-mediated decay. BRCA2-001/Short is expressed more frequently in recurrences and associated with reduced overall survival in breast cancer (87 vs. 121 months; Hazard Ratio = 2.5 [1.18–5.5]). Loss of heterozygosity (LOH) status is discordant in 25% of patient’s primary and recurrent tumors, with switching between both LOH and lack of LOH found. Our study reveals multiple potential drivers of recurrent disease in BRCA1/2 mutation-associated cancer, improving our understanding of tumor evolution and suggesting potential biomarkers., This work was supported by the Tumor Tissue and Biospecimen Bank and the Next Generation Sequencing Core at the University of Pennsylvania (and in particular, we appreciated the help of Dr. Jonathan Schug). We would also like to thank Akoya Biosciences for their technical expertize regarding CODEX analyses. Lastly, the RNA sequencing pipeline used for this study was based on content from Dr. Dan Beiting’s DIY Transcriptomics class at the University of Pennsylvania (Spring 2021), for which we thank him as well. Figure 6 and Supplementary Fig. 15 were created using a licensed version of BioRender. This work was supported by the Basser Center for BRCA at the University of Pennsylvania (S.M.D., K.L.N.), the Gray Foundation Team Science Award (K.L.N.), the V Foundation for Cancer Research BRCA1/2 Convergence Team Award (K.L.N.), the Breast Cancer Research Foundation (S.M.D., K.L.N.) T32 HG009495 (A.K.), Miguel Servet Program (ISCIII) [CPII19/00033] (V.S.) and Asociación Española Contra el Cáncer (A.L.G.).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of High Serum Levels of Growth Factors with Good Outcome in Ischemic Stroke, a Multicenter Study

  • Sobrino, Tomás|||0000-0002-9760-8690
  • Rodríguez-Yáñez, Manuel
  • Campos, Francisco|||0000-0001-8665-1039
  • Iglesias-Rey, Ramón|||0000-0002-9985-9135
  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Pérez de la Ossa, Natalia|||0000-0002-6063-211X
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Martínez-Domeño, Alejandro|||0000-0002-9933-3192
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Castellanos, María del Mar|||0000-0003-3116-1352
  • Serena, Joaquín|||0000-0002-4478-7744
  • Lago, Aida
  • Díez-Tejedor, Exuperio
  • Castillo, José
The main objective of this research work was to study the association of serum levels of growth factors (GF) and SDF-1α with the functional outcome and reduction of lesion volume in ischemic stroke patients. In this multicenter study, 552 patients with non-lacunar stroke (male, 62.1%; mean age, 68.2 ± 11.4) were included within 24 h from symptom onset. The main outcome variable was good functional outcome (modified Rankin Scale [mRS] ≤ 2) at 12 months. Secondary outcome variable was infarct volume (in mL) after 6 ± 3 months. Serum levels of VEGF, Ang-1, G-CSF, BDNF, and SDF-1α were measured by ELISA at admission, 7 ± 1 days, at 3 ± 1 months, and 12 ± 3 months. Except for BDNF, all GF and SDF-1α serum levels showed a peak value at day 7 and remained elevated during the first 3 months (all p < 0.01). High serum levels at day 7 of VEGF (OR, 19.3), Ang-1 (OR, 14.7), G-CSF (OR, 9.6), and SDF-1α (OR, 28.5) were independently associated with good outcome at 12 months (all p < 0.0001). On the other hand, serum levels of VEGF (B, - 21.4), G-CSF (B, - 14.0), Ang-1 (B, - 13.3), and SDF-1α (B, - 44.6) measured at day 7 were independently associated with lesion volume at 6 months (p < 0.01). In summary, high serum levels of VEGF, Ang-1, G-CSF, and SDF-1α at day 7 and 3 months after ischemic stroke are associated with good functional outcome and smaller residual lesion at 1 year of follow-up.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Three-dimensional imaging in myotonic dystrophy type 1

  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Koehorst, Emma
  • Linares-Pardo, Ian
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Guanyabens Busca, Nicolau|||0000-0002-2074-2744
  • Lopez-Osias, Marta
  • Suárez-Mesa, Adrián
  • Hanick, Shaliza Ann
  • Chojnacki, Jakub|||0000-0002-4457-8096
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Nogales, Gisela|||0000-0002-7414-212X
We aimed to determine whether 3D imaging reconstruction allows identifying molecular:clinical associations in myotonic dystrophy type 1 (DM1). We obtained myoblasts from 6 patients with DM1 and 6 controls. We measured cytosine-thymine-guanine (CTG) expansion and detected RNA foci and muscleblind like 1 (MBNL1) through 3D reconstruction. We studied dystrophia myotonica protein kinase (DMPK) expression and splicing alterations of MBNL1, insulin receptor, and sarcoplasmic reticulum Ca(2+)-ATPase 1. Three-dimensional analysis showed that RNA foci (nuclear and/or cytoplasmic) were present in 45%-100% of DM1-derived myoblasts we studied (range: 0-6 foci per cell). RNA foci represented <0.6% of the total myoblast nuclear volume. CTG expansion size was associated with the number of RNA foci per myoblast (r = 0.876 [95% confidence interval 0.222-0.986]) as well as with the number of cytoplasmic RNA foci (r = 0.943 [0.559-0.994]). Although MBNL1 colocalized with RNA foci in all DM1 myoblast cell lines, colocalization only accounted for 1% of total MBNL1 expression, with the absence of DM1 alternative splicing patterns. The number of RNA foci was associated with DMPK expression (r = 0.967 [0.079-0.999]). On the other hand, the number of cytoplasmic RNA foci was correlated with the age at disease onset (r = -0.818 [-0.979 to 0.019]). CTG expansion size modulates RNA foci number in myoblasts derived from patients with DM1. MBNL1 sequestration plays only a minor role in the pathobiology of the disease in these cells. Higher number of cytoplasmic RNA foci is related to an early onset of the disease, a finding that should be corroborated in future studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Palafox, Marta|||0000-0002-1762-3250
  • Scaltriti, Maurizio|||0000-0002-5522-1447
  • Razavi, Pedram
  • Chandarlapaty, Sarat
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Bellet Ezquerra, Meritxell|||0000-0001-8859-8307
  • Serra, Violeta|||0000-0001-6620-1065
  • Aloy, Patrick|||0000-0002-3557-0236
Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients' progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA

  • Radua, Joaquim|||0000-0003-1240-5438
  • Vieta, Eduard|||0000-0002-0548-0053
  • Shinohara, Russell
  • Kochunov, Peter
  • Quidé, Yann|||0000-0002-8569-7139
  • Green, Melissa J.
  • Weickert, Cynthia S.
  • Weickert, Thomas
  • Bruggemann, Jason
  • Kircher, Tilo|||0000-0002-2514-2625
  • Nenadić, Igor|||0000-0002-0749-7473
  • Cairns, Murray J.
  • Seal, Marc
  • Schall, Ulrich
  • Henskens, Frans
  • Fullerton, Janice M.|||0000-0003-4014-4490
  • Mowry, Bryan
  • Pantelis, Christos|||0000-0002-9565-0238
  • Lenroot, Rhoshel
  • Cropley, Vanessa
  • Loughland, Carmel
  • Scott, Rodney
  • Wolf, Daniel H.
  • Satterthwaite, Theodore D.|||0000-0001-7072-9399
  • Tan, Yunlong
  • Sim, Kang|||0000-0003-3209-9626
  • Piras, Fabrizio|||0000-0003-3566-5494
  • Spalletta, Gianfranco|||0000-0002-7432-4249
  • Banaj, Nerisa|||0000-0002-6317-8549
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Solanes, Aleix|||0000-0002-2491-200X
  • Albajes-Eizagirre, Anton
  • Canales-Rodriguez, Erick Jorge|||0000-0001-6421-2633
  • Sarro, Salvador
  • Giorgio, Annabella Di
  • Bertolino, Alessandro
  • Stäblein, Michael
  • Oertel, Viola
  • Knöchel, Christian
  • Borgwardt, Stefan
  • du Plessis, Stefan
  • Yun, Je-Yeon|||0000-0002-5531-2410
  • Kwon, Jun Soo|||0000-0002-1060-1462
  • Dannlowski, Udo|||0000-0002-0623-3759
  • Hahn, Tim|||0000-0002-8929-4134
  • Grotegerd, Dominik
  • Alloz, Clara
  • Arango, Celso|||0000-0003-3382-4754
  • Janssen, Joost|||0000-0001-7613-2067
  • Díaz-Caneja, Covadonga M.|||0000-0001-8538-3175
  • Jiang, Wenhao
  • Calhoun, Vince
  • Ehrlich, Stefan|||0000-0003-2132-4445
  • Yang, Kun
  • Cascella, Nicola G.
  • Takayanagi, Yoichiro
  • Sawa, Akira
  • Tomyshev, Alexander
  • Lebedeva, Irina
  • Kaleda, Vasily
  • Kirschner, Matthias
  • Hoschl, Cyril
  • Tomecek, David
  • Skoch, Antonin
  • van Amelsvoort, Therese
  • Bakker, Geor
  • James, Anthony|||0000-0002-2742-8328
  • Preda, Adrian
  • Weideman, Andrea
  • Stein, Dan J.|||0000-0001-7218-7810
  • Howells, Fleur
  • Uhlmann, Anne|||0000-0002-1753-7811
  • Temmingh, Henk
  • López-Jaramillo, Carlos
  • Díaz-Zuluaga, Ana M..
  • Fortea, Lydia|||0000-0001-6778-2316
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Solana, Elisabeth|||0000-0001-7973-2439
  • Llufriu, Sara|||0000-0003-4273-9121
  • Jahanshad, Neda|||0000-0003-4401-8950
  • Thompson, Paul
  • Turner, Jessica A.
  • van Erp, Theo
A common limitation of neuroimaging studies is their small sample sizes. To overcome this hurdle, the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium combines neuroimaging data from many institutions worldwide. However, this introduces heterogeneity due to different scanning devices and sequences. ENIGMA projects commonly address this heterogeneity with random-effects meta-analysis or mixed-effects mega-analysis. Here we tested whether the batch adjustment method, ComBat, can further reduce site-related heterogeneity and thus increase statistical power. We conducted random-effects meta-analyses, mixed-effects mega-analyses and ComBat mega-analyses to compare cortical thickness, surface area and subcortical volumes between 2897 individuals with a diagnosis of schizophrenia and 3141 healthy controls from 33 sites. Specifically, we compared the imaging data between individuals with schizophrenia and healthy controls, covarying for age and sex. The use of ComBat substantially increased the statistical significance of the findings as compared to random-effects meta-analyses. The findings were more similar when comparing ComBat with mixed-effects mega-analysis, although ComBat still slightly increased the statistical significance. ComBat also showed increased statistical power when we repeated the analyses with fewer sites. Results were nearly identical when we applied the ComBat harmonization separately for cortical thickness, cortical surface area and subcortical volumes. Therefore, we recommend applying the ComBat function to attenuate potential effects of site in ENIGMA projects and other multi-site structural imaging work. We provide easy-to-use functions in R that work even if imaging data are partially missing in some brain regions, and they can be trained with one data set and then applied to another (a requirement for some analyses such as machine learning).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mindfulness-Based Program Plus Amygdala and Insula Retraining (MAIR) for the Treatment of Women with Fibromyalgia, a Pilot Randomized Controlled Trial

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Gasión, Virginia
  • Navarro-Gil, Mayte|||0000-0003-4842-0453
  • Morillo, Héctor|||0000-0002-9852-2776
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Borràs, Xavier|||0000-0003-3972-1385
  • Tops, Mattie
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Feliu-Soler, Albert|||0000-0003-2810-7670
The lack of highly effective treatments for fibromyalgia (FM) represents a great challenge for public health. The objective of this parallel, pilot randomized controlled trial (RCT) was two-fold: (1) to analyze the clinical effects of mindfulness plus amygdala and insula retraining (MAIR) compared to a structurally equivalent active control group of relaxation therapy (RT) in the treatment of FM; and (2) to evaluate its impact on immune-inflammatory markers and brain-derived neurotrophic factor (BDNF)in serum. A total of 41 FM patients were randomized into two study arms: MAIR (intervention group)and RT (active control group), both as add-ons of treatment as usual. MAIR demonstrated significantly greater reductions in functional impairment, anxiety, and depression, as well as higher improvements in mindfulness, and self-compassion at post-treatment and follow-up, with moderate to large effectsizes. Significant decreases in pain catastrophizing and psychological inflexibility and improvementsin clinical severity and health-related quality of life were found at follow-up, but not at post-treatment,showing large effect sizes. The number needed to treat was three based on the criteria of ≥50% Fibromyalgia Impact Questionnaire (FIQ) reduction post-treatment. Compared to RT, the MAIRshowed significant decreases in BDNF. No effect of MAIR was observed in immune-inflammatorybiomarkers (i.e., TNF-α, IL-6, IL-10, and hs-CRP). In conclusion, these results suggest that MAIR, as an adjuvant of treatment-as-usual (TAU), appears to be effective for the management of FM symptomsand for reducing BDNF levels in serum.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis

  • Isidro-Hernández, Marta
  • Mayado, Andrea
  • Casado-García, Ana
  • Martínez-Cano, Jorge
  • Palmi, Chiara
  • Fazio, Grazia
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Raboso-Gallego, Javier
  • Blanco, Óscar
  • Alonso-López, Diego
  • De Las Rivas, Javier
  • Jiménez, Rafael|||0000-0003-4103-8219
  • García Criado, Francisco Javier
  • García Cenador, María Begoña
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Cazzaniga, Giovanni|||0000-0003-2955-4528
  • Cobaleda, Cesar|||0000-0003-3807-9204
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
PAX5 is one of the most frequently mutated genes in B-cell acute lymphoblastic leukemia (B-ALL), and children with inherited preleukemic PAX5 mutations are at a higher risk of developing the disease. Abnormal profiles of inflammatory markers have been detected in neonatal blood spot samples of children who later developed B-ALL. However, how inflammatory signals contribute to B-ALL development is unclear. Here, we demonstrate that Pax5 heterozygosis, in the presence of infections, results in the enhanced production of the inflammatory cytokine interleukin-6 (IL-6), which appears to act in an autocrine fashion to promote leukemia growth. Furthermore, in vivo genetic downregulation of IL-6 in these Pax5 heterozygous mice retards B-cell leukemogenesis, and in vivo pharmacologic inhibition of IL-6 with a neutralizing antibody in Pax5 mutant mice with B-ALL clears leukemic cells. Additionally, this novel IL-6 signaling paradigm identified in mice was also substantiated in humans. Altogether, our studies establish aberrant IL6 expression caused by Pax5 loss as a hallmark of Pax5-dependent B-ALL and the IL6 as a therapeutic vulnerability for B-ALL characterized by PAX5 loss.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Social inequities in the impact of COVID-19 lockdown measures on the mental health of a large sample of the Colombian population (PSY-COVID study)

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Useche-Aldana, Bernardo
  • Ochoa, Pedro Pablo|||0000-0003-3035-8647
  • Rojas-Gualdrón, Diego Fernando|||0000-0002-2293-0431
  • Mateo Canedo, Corel|||0000-0002-0620-9257
  • Carmona Cervelló, Meritxell|||0000-0003-0907-9168
  • Crespo-Puig, Neus|||0000-0001-8036-6739
  • Selva Olid, Clara|||0000-0001-7390-9889
  • Muro Rodríguez, Anna|||0000-0002-1331-9921
  • Méndez Ulrich, Jorge Luis|||0000-0001-9718-0607
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
The identification of general population groups particularly vulnerable to the impact of COVID-19 lockdown measures on mental health and the development of healthcare policies are priority challenges in the current and future pandemics. This study aimed to identify the personal and social determinants of the impact of COVID-19 lockdown measures on mental health in a large sample of the Colombian population. In this cross-sectional study, an anonymous online survey was answered by 18,061 participants from the general population residing in Colombia during the first wave of the COVID-19 outbreak (from 20 May to 20 June 2020). The risk of depression, anxiety, and somatization disorders were measured using the Patient Health Questionnaire (PHQ-2), Generalized Anxiety Disorder Scale (GAD-2), and Somatic Symptom Questionnaire (SSQ-5), respectively. Overall, 35% of participants showed risk of depression, 29% of anxiety, and 31% of somatization. According to the analysis of social determinants of health, the most affected groups were people with low incomes, students, and young adults (18-29 years). Specifically, low-income young females were the most at-risk population group. These findings show how the lockdown measures affected the general population's mental health in Colombia and highlight some social risk factors in health.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Hernández-Negrín, Halbert
  • Borràs, Xavier|||0000-0003-3972-1385
  • Suso-Ribera, Carlos|||0000-0002-2655-1017
  • García Palacios, Azucena|||0000-0001-9250-8714
  • Muchart, Jordi
  • Munuera, Josep|||0000-0001-5154-1796
  • D'Amico, Francesco|||0000-0001-7995-826X
  • Maes, Michael|||0000-0002-2012-871X
  • Younger, Jarred W.
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Rozadilla-Sacanell, Antoni|||0000-0002-7555-189X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
There is evidence that low-dose naltrexone (LDN; <5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term follow-ups have been carried out. The INNOVA study will evaluate the add-on efficacy, safety, cost-utility and neurobiological effects of LDN for reducing pain in patients with FMS, with a 1-year follow-up. A single-site, prospective, randomised, double-blinded, placebo-controlled, parallel design phase III trial will be performed. Eligibility criteria include being adult, having a diagnosis of FMS and experiencing pain of 4 or higher on a 10-point numerical rating scale. Participants will be randomised to a LDN intervention group (4.5 mg/day) or to a placebo control group. Clinical assessments will be performed at baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3). The primary endpoint will be pain intensity. A sample size of 60 patients per study arm (120 in total), as calculated prior to recruitment for sufficient power, will be monitored between January 2022 and August 2024. Assessment will also include daily ecological momentary evaluations of FMS-related symptoms (eg, pain intensity, fatigue and sleep disturbance), and side effects via ecological momentary assessment through the Pain Monitor app during the first 3 months. Costs and quality-adjusted life years will be also calculated. Half of the participants in each arm will be scanned with MRI at T0 and T1 for changes in brain metabolites related to neuroinflammation and central sensitisation. Inflammatory biomarkers in serum will also be measured. This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and community engagement activities. .
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Focusing on Comorbidity-A Novel Meta-Analytic Approach and Protocol to Disentangle the Specific Neuroanatomy of Co-occurring Mental Disorders

  • Fortea, Lydia|||0000-0001-6778-2316
  • Albajes-Eizagirre, Anton
  • Yao, Yuan-Wei
  • Soler, Edu
  • Verdolini, Norma|||0000-0001-9488-2881
  • Hauson, Alexander O.
  • Fortea, Adriana
  • Madero, Santiago|||0000-0002-1123-4211
  • Solanes, Aleix|||0000-0002-2491-200X
  • Wollman, Scott C.
  • Serra Blasco, Maria|||0000-0001-5793-9906
  • Wise, Toby
  • Lukito, Steve
  • Picó-Pérez, Maria|||0000-0002-1573-2445
  • Carlisi, Christina
  • Zhang, JinTao
  • Pan, PingLei
  • Farré-Colomés, Álvar
  • Arnone, Danilo
  • Kempton, Matthew|||0000-0003-3541-9947
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Rubia, Katya|||0000-0002-1410-7701
  • Norman, Luke
  • Fusar-Poli, Paolo|||0000-0003-3582-6788
  • Mataix-Cols, David|||0000-0002-4545-0924
  • Valentí, Marc
  • Via, Esther|||0000-0002-2331-3232
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Solmi, Marco|||0000-0003-4877-7233
  • Shin, Jae I.
  • Vieta, Eduard|||0000-0002-0548-0053
  • Radua, Joaquim|||0000-0003-1240-5438
In mental health, comorbidities are the norm rather than the exception. However, current meta-analytic methods for summarizing the neural correlates of mental disorders do not consider comorbidities, reducing them to a source of noise and bias rather than benefitting from their valuable information. We describe and validate a novel neuroimaging meta-analytic approach that focuses on comorbidities. In addition, we present the protocol for a meta-analysis of all major mental disorders and their comorbidities. The novel approach consists of a modification of Seed-based d Mapping-with Permutation of Subject Images (SDM-PSI) in which the linear models have no intercept. As in previous SDM meta-analyses, the dependent variable is the brain anatomical difference between patients and controls in a voxel. However, there is no primary disorder, and the independent variables are the percentages of patients with each disorder and each pair of potentially comorbid disorders. We use simulations to validate and provide an example of this novel approach, which correctly disentangled the abnormalities associated with each disorder and comorbidity. We then describe a protocol for conducting the new meta-analysis of all major mental disorders and their comorbidities. Specifically, we will include all voxel-based morphometry (VBM) studies of mental disorders for which a meta-analysis has already been published, including at least 10 studies. We will use the novel approach to analyze all included studies in two separate single linear models, one for children/adolescents and one for adults. The novel approach is a valid method to focus on comorbidities. The meta-analysis will yield a comprehensive atlas of the neuroanatomy of all major mental disorders and their comorbidities, which we hope might help develop potential diagnostic and therapeutic tools.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cold stress protein RBM3 responds to hypothermia and is associated with good stroke outcome

  • Ávila-Gómez, Paulo
  • Vieites-Prado, Alba
  • Dopico-López, Antonio
  • Bashir, Saima
  • Fernández-Susavila, Héctor
  • Gubern, Carme|||0000-0001-8378-4477
  • Pérez-Mato, María
  • Correa-Paz, Clara
  • Iglesias-Rey, Ramón|||0000-0002-9985-9135
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Wellmann, Sven
  • Montaner, Joan|||0000-0003-4845-2279
  • Serena, Joaquín|||0000-0002-4478-7744
  • Castillo, José
  • Hervella, Pablo|||0000-0003-1249-6333
  • Campos, Francisco|||0000-0001-8665-1039
RNA-binding motif protein 3 is a molecular marker of hypothermia that has proved neuroprotective in neurodegenerative disease models. However, its relationship to the well-recognized therapeutic effect of hypothermia in ischaemic stroke had not been studied. In this work, the expression of RNA-binding motif protein 3 was investigated in ischaemic animal models subjected to systemic and focal brain hypothermia, specifically the effects of RNA-binding motif protein 3 silencing and overexpression on ischaemic lesions. Moreover, the association of RNA-binding motif protein 3 levels with body temperature and clinical outcome was evaluated in two independent cohorts of acute ischaemic stroke patients (n = 215); these levels were also determined in a third cohort of 31 patients derived from the phase III EuroHYP-1 trial of therapeutic cooling in ischaemic stroke. The preclinical data confirmed the increase of brain RNA-binding motif protein 3 levels in ischaemic animals subjected to systemic and focal hypothermia; this increase was selectively higher in the cooled hemisphere of animals undergoing focal brain hypothermia, thus confirming the direct effect of hypothermia on RNA-binding motif protein 3 expression, while RNA-binding motif protein 3 up-regulation in ischaemic brain regions led to functional recovery. Clinically, patients with body temperature <37.5°C in the first two cohorts had higher RNA-binding motif protein 3 values at 24 h and good outcome at 3 months post-ischaemic stroke, while RNA-binding motif protein 3 levels in the cooled third cohort tended to exceed those in placebo-treated patients. These results make RNA-binding motif protein 3 a molecular marker associated with the effect of hypothermia in ischaemic stroke and suggest its potential application as a promising protective target. Hypothermia is an effective neuroprotective treatment in stroke. We have demonstrated that the expression of RBM3 is increased under hypothermia treatment in animal models of ischaemia and stroke patients. These results evidence the potential application of RBM3 as a promising protective target against ischaemia
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cost-Utility of Attachment-Based Compassion Therapy (ABCT) for Fibromyalgia Compared to Relaxation, A Pilot Randomized Controlled Trial

  • D'Amico, Francesco|||0000-0001-7995-826X
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Peñarrubía-María, María T.
  • Navarro-Gil, Mayte|||0000-0003-4842-0453
  • Van Gordon, William
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Luciano, Juan Vicente|||0000-0003-0750-1599
A recent study has supported the efficacy of Attachment-Based Compassion Therapy (ABCT) compared to relaxation (REL) for the management of fibromyalgia (FM). The main objective of this paper is to examine the cost-utility of ABCT compared to REL in terms of effects on quality-adjusted life years (QALYs) as well as healthcare costs. Forty-two Spanish patients with FM received 8 weekly group sessions of ABCT or REL. Data collection took place at pre- and 3-month follow-up. Cost-utility of the two treatment groups (ABCT vs. REL) was compared by examining treatment outcomes in terms of QALYs (obtained with the EQ-5D-3L) and healthcare costs (data about service use obtained with the Client Service Receipt Inventory). Data analyses were computed from a completers, ITT, and per protocol approach. Data analysis from the healthcare perspective revealed that those patients receiving ABCT exhibited larger improvements in quality of life than those doing relaxation, while being less costly 3 months after their 8-week treatment program had ended (completers: incremental cost M, 95% CI = €-194.1 (-450.3 to 356.1); incremental effect M, 95% CI = 0.023 QALYs (0.010 to 0.141)). Results were similar using an ITT approach (incremental cost M, 95% CI = €-256.3 (-447.4 to -65.3); incremental effect M, 95% CI = 0.021 QALYs (0.009 to 0.033)). A similar pattern of results were obtained from the per protocol approach. This RCT has contributed to the evidence base of compassion-based interventions and provided useful information about the cost-utility of ABCT for FM patients when compared to relaxation. However, the small sample size and short follow-up period limited the generalizability of the findings.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy, cost-utility and physiological effects of Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in patients with chronic low back pain and depression, study protocol of a randomised, controlled trial including mobile-technology-based ecological momentary assessment (IMPACT study)

  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Forero, Carlos G.|||0000-0002-5245-0076
  • Cristóbal Narváez, Paula|||0000-0001-8184-6347
  • Suso-Ribera, Carlos|||0000-0002-2655-1017
  • García Palacios, Azucena|||0000-0001-9250-8714
  • Colomer-Carbonell, Ariadna|||0000-0001-8923-6316
  • Pérez-Aranda, Adrián|||0000-0002-1602-3413
  • Andrés Rodríguez, Laura|||0000-0001-5133-9811
  • McCracken, Lance M.|||0000-0002-9734-0153
  • D'Amico, Francesco|||0000-0001-7995-826X
  • Estivill, Pere|||0000-0002-7917-6134
  • Carreras-Marcos, Bernat|||0000-0001-5224-1453
  • Montes-Pérez, Antonio
  • Comps, Olga|||0000-0002-0977-477X
  • Esteve, Montserrat|||0000-0003-2128-7859
  • Grasa, Mar
  • Rosa de la Cruz, Araceli|||0000-0001-6935-3785
  • Cuesta-Vargas, Antonio I.|||0000-0002-8880-4315
  • Maes, Michael|||0000-0002-2012-871X
  • Borràs, Xavier|||0000-0003-3972-1385
  • Edo Izquierdo, Sílvia|||0000-0002-6564-3475
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Castaño Asins, Juan Ramon|||0000-0001-6571-503X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
The IMPACT study focuses on chronic low back pain (CLBP) and depression symptoms, a prevalent and complex problem that represents a challenge for health professionals. Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively. The objectives of this 12 month, multicentre, randomised, controlled trial (RCT) are (i) to examine the efficacy and cost-utility of adding a group-based form of ACT or BATD to treatment-as-usual (TAU) for patients with CLBP and moderate to severe levels of depressive symptoms; (ii) identify pre-post differences in levels of some physiological variables and (iii) analyse the role of polymorphisms in the FKBP5 gene, psychological process measures and physiological variables as mediators or moderators of long-term clinical changes. Participants will be 225 patients with CLBP and moderate to severe depression symptoms recruited at Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) and Hospital del Mar (Barcelona, Spain), randomly allocated to one of the three study arms: TAU vs TAU+ACT versus TAU+BATD. A comprehensive assessment to collect clinical variables and costs will be conducted pretreatment, post-treatment and at 12 months follow-up, being pain interference the primary outcome measure. The following physiological variables will be considered at pretreatment and post-treatment assessments in 50% of the sample: immune-inflammatory markers, hair cortisol and cortisone, serum cortisol, corticosteroid-binding globulin and vitamin D. Polymorphisms in the FKBP5 gene (rs3800373, rs9296158, rs1360780, rs9470080 and rs4713916) will be analysed at baseline assessment. Moreover, we will include mobile-technology-based ecological momentary assessment, through the Pain Monitor app, to track ongoing clinical status during ACT and BATD treatments. Linear mixed-effects models using restricted maximum likelihood, and a full economic evaluation applying bootstrapping techniques, acceptability curves and sensitivity analyses will be computed. This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu and Hospital del Mar. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and various community engagement activities.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Unhappy while depressed, examining the dimensionality, reliability and validity of the subjective happiness scale in a spanish sample of patients with depressive disorders

  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Diego-Adeliño, Javier de|||0000-0001-9708-2441
  • Luciano, Juan Vicente|||0000-0003-0750-1599
  • Iraurgi, Ioseba|||0000-0002-0143-9539
  • Alemany Santamaría, Carlo|||0000-0001-8363-4786
  • Puigdemont, Dolors|||0000-0002-5729-0972
  • Pérez Solà, Víctor|||0000-0002-5825-2337
  • Portella Moll, Maria J., 1975-|||0000-0002-2007-9516
  • Trujols, Joan|||0000-0003-0396-7105
Despite the considerable amount of research evidence on the significant role of subjective happiness on mental health, there is no psychometric study of the Subjective Happiness Scale (SHS) in psychiatric samples. This study was aimed at exploring the psychometric properties of the SHS in a Spanish sample of patients with depressive disorders. Participants were 174 patients with a depressive disorder (70% diagnosed as major depressive disorder) who completed the SHS, the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16), and the EQ-5D Visual Analogue Scale (EQ-5D VAS). Depressive symptoms were also assessed by means of the 17-item Hamilton Depression Rating Scale (HDRS17) and the Clinical Global Impression-Severity (CGI-S) Scale. Dimensionality, internal consistency reliability, construct validity, and responsiveness to change of the SHS were examined. Confirmatory factor analysis replicated the original one-factor structure of the scale. The SHS exhibited good-to-excellent results for internal consistency (α = 0.83) and for convergent [EQ-5D VAS (r = 0.71)] and divergent [QIDS-SR16 (r = -0.72), HDRS17 (r = -0.60) and CGI-S (r = -0.61)] construct validity. The ability of the SHS to differentiate between depression severity levels as well as its responsiveness to clinical change were both highly satisfactory (p < 0.001 in both cases). The SHS retained the soundness of psychometric properties showed in non-clinical samples in a sample of patients with depressive disorders, which supports its use as a reliable and valid outcome measure in the treatment of such disorders.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus

  • García-Crespo, Carlos|||0000-0001-6561-5389
  • Gallego, Isabel
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • de Ávila, Ana Isabel
  • Martínez-González, Brenda|||0000-0002-4482-5181
  • Vázquez-Sirvent, Lucía
  • Lobo-Vega, Rebeca|||0000-0002-4882-6763
  • Moreno del Olmo, Elena|||0000-0002-2301-4558
  • Gómez, Jordi
  • Briones Llorente, Carlos|||0000-0003-2213-8353
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Quer, Josep|||0000-0003-0014-084X
  • Domingo, Esteban
  • Perales Viejo, Celia|||0000-0003-1618-1937
Replication of RNA viruses is characterized by exploration of sequence space which facilitates their adaptation to changing environments. It is generally accepted that such exploration takes place mainly in response to positive selection, and that further diversification is boosted by modifications of virus population size, particularly bottleneck events. Our recent results with hepatitis C virus (HCV) have shown that the expansion in sequence space of a viral clone continues despite prolonged replication in a stable cell culture environment. Diagnosis of the expansion was based on the quantification of diversity indices, the occurrence of intra-population mutational waves (variations in mutant frequencies), and greater individual residue variations in mutant spectra than those anticipated from sequence alignments in data banks. In the present report, we review our previous results, and show additionally that mutational waves in amplicons from the NS5A-NS5B-coding region are equally prominent during HCV passage in the absence or presence of the mutagenic nucleotide analogues favipiravir or ribavirin. In addition, by extending our previous analysis to amplicons of the NS3- and NS5A-coding region, we provide further evidence of the incongruence between amino acid conservation scores in mutant spectra from infected patients and in the Los Alamos National Laboratory HCV data banks. We hypothesize that these observations have as a common origin a permanent state of HCV population disequilibrium even upon extensive viral replication in the absence of external selective constraints or changes in population size. Such a persistent disequilibrium-revealed by the changing composition of the mutant spectrum-may facilitate finding alternative mutational pathways for HCV antiviral resistance. The possible significance of our model for other genetically variable viruses is discussed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials

  • Taipale, Heidi
  • Schneider-Thoma, Johannes
  • Pinzón-Espinosa, Justo|||0000-0002-3084-7793
  • Radua, Joaquim|||0000-0003-1240-5438
  • Efthimiou, Orestis
  • Vinkers, Christiaan H.|||0000-0003-3698-0744
  • Mittendorfer-Rutz, Ellenor
  • Cardoner, Narcís|||0000-0001-9633-0888
  • Pintor Pérez, Luis|||0000-0002-8730-7296
  • Tanskanen, Antti
  • Tomlinson, Anneka
  • Fusar-Poli, Paolo|||0000-0003-3582-6788
  • Cipriani, Andrea
  • Vieta, Eduard|||0000-0002-0548-0053
  • Leucht, Stefan
  • Tiihonen, Jari
  • Luykx, Jurjen J.|||0000-0002-6439-2774
This cohort study quantifies the proportion of real-world individuals with schizophrenia spectrum disorders who would be ineligible for participation in randomized clinical trials and explores whether clinical outcomes differ between eligible and ineligible individuals. What percentage of patients with schizophrenia in the real world are represented in randomized clinical trials (RCTs) and do their outcomes differ from those not represented in RCTs? In this study of 25 259 real-world individuals with diagnoses of schizophrenia spectrum disorders recorded in national patient registries in Finland and Sweden, about a fifth were represented in RCTs and their outcomes were better than of those individuals with schizophrenia not meeting RCT inclusion criteria. Future research should consider the heterogeneity of individuals with schizophrenia and the patient groups typically ineligible for participation; RCTs may become more inclusive by representing a broader spectrum of individuals with schizophrenia and by targeting specific currently underrepresented groups. Most evidence about efficacy and safety of antipsychotics in schizophrenia spectrum disorders relies on randomized clinical trials (RCTs). However, owing to their strict eligibility criteria, RCTs represent only a part of the real-world population (ie, unselected patients seen in everyday clinical practice), which may result in an efficacy-effectiveness gap. To quantify the proportion of real-world individuals with schizophrenia spectrum disorders who would be ineligible for participation in RCTs, and to explore whether clinical outcomes differ between eligible and ineligible individuals. This study applied eligibility criteria typically used in RCTs for relapse prevention in schizophrenia spectrum disorders to real-world populations. Individuals with diagnoses of schizophrenia spectrum disorders recorded in national patient registries in Finland and Sweden were identified. Individuals who had used antipsychotics continuously for 12 weeks in outpatient care were selected. Individuals were followed up for up to 1 year while they were receiving maintenance treatment with any second-generation antipsychotic (excluding clozapine). Follow-up was censored at treatment discontinuation, initiation of add-on antipsychotics, death, and end of database linkage. Proportions of RCT-ineligible individuals with schizophrenia spectrum disorders owing to any and specific RCT exclusion criteria. The risk of hospitalization due to psychosis within 1-year follow-up in ineligible vs eligible persons were compared using hazard ratios (HR) and corresponding 95% CIs. The mean (SD) age in the Finnish cohort (n = 17 801) was 47.5 (13.8) years and 8972 (50.4%) were women; the mean (SD) age in the Swedish cohort (n = 7458) was 44.8 (12.5) years and 3344 (44.8%) were women. A total of 20 060 individuals (79%) with schizophrenia spectrum disorders would be ineligible for RCTs (Finnish cohort: 14 221 of 17 801 [79.9%]; Swedish cohort: 5839 of 7458 [78.3%]). Most frequent reasons for ineligibility were serious somatic comorbidities and concomitant antidepressant/mood stabilizer use. Risks of hospitalization due to psychosis was higher among ineligible than eligible individuals (Finnish cohort: 18.4% vs 17.2%; HR, 1.14 [95% CI, 1.04-1.24]; Swedish cohort: 20.1% vs 14.8%; HR, 1.47 [95% CI, 1.28-1.92]). The largest risks of hospitalization due to psychosis were observed in individuals ineligible owing to treatment resistance, tardive dyskinesia, and history of suicide attempts. Finally, with more ineligibility criteria met, larger risks of hospitalization due to psychosis were observed in both countries. RCTs may represent only about a fifth of real-world individuals with schizophrenia spectrum disorders. Underrepresented (ineligible) patients with schizophrenia spectrum disorders have moderately higher risks of admission due to psychosis while receiving maintenance treatment than RCT-eligible patients. These findings set the stage for future studies targeting real-world populations currently not represented by RCTs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder

  • Galván, Sandra Torres
  • Flores-López, María|||0000-0003-3489-1465
  • Romero-Sanchiz, Pablo
  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Porras-Perales, Oscar
  • Nogueira-Arjona, Raquel
  • Mayoral-Cleries, Fermín
  • Araos, Pedro|||0000-0001-5172-8796
  • Serrano, Antonia
  • Muga, Roberto|||0000-0001-6301-431X
  • Pavón, Francisco Javier
  • García Marchena, Nuria|||0000-0002-0575-3613
  • de Fonseca, Fernando Rodríguez
Granulocyte colony-stimulating factor (G-CSF) has raised much interest because of its role in cocaine addiction in preclinical models. We explored the plasma concentrations of G-CSF in patients diagnosed with substance use disorder (SUD) and highly comorbid psychiatric disorders. In particular, we investigated the association between G-CSF concentrations and comorbid major depressive disorder (MDD) in patients with cocaine and alcohol use disorders (CUD and AUD, respectively). Additionally, patients with MDD but not SUD were included in the study. Three hundred and eleven participants were enrolled in this exploratory study: 136 control subjects, 125 patients with SUD (SUD group) from outpatient treatment programs for cocaine (N = 60, cocaine subgroup) and alcohol (N = 65, alcohol subgroup), and 50 patients with MDD but not SUD (MDD group) from primary-care settings. Participants were assessed based on DSM-IV-TR criteria, and a blood sample was collected to examine the plasma concentrations of G-CSF. G-CSF concentrations were negatively correlated with age in the entire sample (r = - 0.233, p < 0.001) but not in the patients with MDD. G-CSF concentrations were lower in patients with SUD than in controls (p < 0.05), specifically in the cocaine subgroup (p < 0.05). Patients with SUD and comorbid MDD had lower G-CSF concentrations than patients with SUD but not comorbid MDD or controls (p < 0.05). In contrast, patients with MDD but not SUD showed no differences compared with their controls. The negative association between G-CSF concentrations and age in the sample was not observed in patients with MDD. G-CSF concentrations were decreased in patients with SUD and comorbid MDD but not in patients with MDD. Therefore, G-CSF may be useful to improve the stratification of patients with dual diagnosis seeking treatment. Further investigation is needed to explore the impact of sex and type of drug on the expression of G-CSF.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy

  • Llorens-Revull, Meritxell|||0000-0002-8671-8907
  • Costafreda Salvany, Maria Isabel|||0000-0002-3114-3034
  • Rico, Angie
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Soria, Maria Eugenia
  • Píriz-Ruzo, Sofía
  • Vargas-Accarino, Elena|||0000-0002-2521-0368
  • Gabriel-Medina, Pablo|||0000-0003-3079-6364
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Quer, Josep|||0000-0003-0014-084X
  • Sauleda, Silvia|||0000-0001-7343-9557
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Bes, Marta|||0000-0001-6103-072X
HCV CD4+ and CD8+ specific T cells responses are functionally impaired during chronic hepatitis C infection. DAAs therapies eradicate HCV infection in more than 95% of treated patients. However, the impact of HCV elimination on immune responses remain controversial. Here, we aimed to investigate whether HCV cure by DAAs could reverse the impaired immune response to HCV. We analyzed 27 chronic HCV infected patients undergoing DAA treatment in tertiary care hospital, and we determined the phenotypical and functional changes in both HCV CD8+ and CD4+ specific T-cells before and after viral clearance. PD-1, TIM-3 and LAG-3 cell-surface expression was assessed by flow cytometry to determine CD4+ T cell exhaustion. Functional responses to HCV were analyzed by IFN-Ɣ ELISPOT, intracellular cytokine staining (IL-2 and IFN-Ɣ) and CFSE-based proliferation assays. We observed a significant decrease in the expression of PD-1 in CD4+ T-cells after 12 weeks of viral clearance in non-cirrhotic patients (p = 0.033) and in treatment-naive patients (p = 0.010), indicating a partial CD4 phenotype restoration. IFN-Ɣ and IL-2 cytokines production by HCV-specific CD4+ and CD8+ T cells remained impaired upon HCV eradication. Finally, a significant increase of the proliferation capacity of both HCV CD4+ and CD8+ specific T-cells was observed after HCV elimination by DAAs therapies. Our results show that in chronically infected patients HCV elimination by DAA treatment lead to partial reversion of CD4+ T cell exhaustion. Moreover, proliferative capacity of HCV-specific CD4+ and CD8+ T cells is recovered after DAA's therapies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Optimal opportunistic screening of atrial fibrillation using pulse palpation in cardiology outpatient clinics, Who and how

  • Bañeras, Jordi|||0000-0002-7395-0862
  • Pariggiano, Ivana
  • Ródenas-Alesina, Eduard|||0000-0003-1638-7820
  • Oristrell, Gerard|||0000-0003-3217-987X
  • Escalona Silva, Roxana Andreina
  • Miranda, Berta|||0000-0003-1617-1050
  • Rello, Pau|||0000-0001-9800-7152
  • Soriano-Colomé, Toni|||0000-0002-2121-6084
  • Gordon, Blanca
  • Belahnech, Yassin|||0000-0003-0723-1023
  • Calabrò, Paolo|||0000-0002-5018-830X
  • García-Dorado, David|||0000-0002-1126-1279
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
  • Radua, Joaquim|||0000-0003-1240-5438
Atrial fibrillation (AF) remain a prevalent undiagnosed condition frequently encountered in primary care. We aimed to find the parameters that optimize the diagnostic accuracy of pulse palpation to detect AF. We also aimed to create a simple algorithm for selecting which individuals would benefit from pulse palpation and, if positive, receive an ECG to detect AF. Nurses from four Cardiology outpatient clinics palpated 7,844 pulses according to a randomized list of arterial territories and durations of measure and immediately followed by a 12-lead ECG, which we used as the reference standard. We calculated the sensitivity and specificity of the palpation parameters. We also assessed whether diagnostic accuracy depended on the nurse's experience or on a list of clinical factors of the patients. With this information, we estimated the positive predictive values and false omission rates according to very few clinical factors readily available in primary care (age, sex, and diagnosis of heart failure) and used them to create the algorithm. The parameters associated with the highest diagnostic accuracy were palpation of the radial artery and classifying as irregular those palpations in which the nurse was uncertain about pulse regularity or unable to palpate pulse (sensitivity = 79%; specificity = 86%). Specificity decreased with age. Neither the nurse's experience nor any investigated clinical factor influenced diagnostic accuracy. We provide the algorithm to select the ≥40 years old individuals that would benefit from a pulse palpation screening: a) do nothing in <60 years old individuals without heart failure; b) do ECG in ≥70 years old individuals with heart failure; c) do radial pulse palpation in the remaining individuals and do ECG if the pulse is irregular or you are uncertain about its regularity or unable to palpate it. Opportunistic screening for AF using optimal pulse palpation in candidate individuals according to a simple algorithm may have high effectiveness in detecting AF in primary care
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

  • Solanes, Aleix|||0000-0002-2491-200X
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Janssen, Joost|||0000-0001-7613-2067
  • Amoretti, Silvia|||0000-0001-6017-2734
  • Lobo, Antonio|||0000-0002-9098-655X
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Arango, Celso|||0000-0003-3382-4754
  • Vieta, Eduard|||0000-0002-0548-0053
  • Castro-Fornieles, Josefina|||0000-0003-0632-2687
  • Bergé Baquero, Daniel|||0000-0003-2544-1016
  • Albacete, Auria|||0000-0003-4156-4972
  • Giné Serven, Eloi|||0000-0002-3130-5566
  • Parellada, Mara|||0000-0001-7977-3601
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Radua, Joaquim|||0000-0003-1240-5438
Detecting patients at high relapse risk after the first episode of psychosis (HRR-FEP) could help the clinician adjust the preventive treatment. To develop a tool to detect patients at HRR using their baseline clinical and structural MRI, we followed 227 patients with FEP for 18-24 months and applied MRIPredict. We previously optimized the MRI-based machine-learning parameters (combining unmodulated and modulated gray and white matter and using voxel-based ensemble) in two independent datasets. Patients estimated to be at HRR-FEP showed a substantially increased risk of relapse (hazard ratio = 4.58, P < 0.05). Accuracy was poorer when we only used clinical or MRI data. We thus show the potential of combining clinical and MRI data to detect which individuals are more likely to relapse, who may benefit from increased frequency of visits, and which are unlikely, who may be currently receiving unnecessary prophylactic treatments. We also provide an updated version of the MRIPredict software.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

  • Shah, Jennifer B.|||0000-0001-9908-9874
  • Pueschl, Dana
  • Wubbenhorst, Bradley
  • Fan, Mengyao
  • Pluta, John
  • D'Andrea, Kurt
  • Hubert, Anna P.
  • Shilan, Jake S.
  • Zhou, Wenting
  • Kraya, Adam A.
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ruan, Catherine
  • Serra, Violeta|||0000-0001-6620-1065
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Feldman, Michael
  • Morin, Pat J.
  • Nayak, Anupma
  • Maxwell, Kara N.|||0000-0001-8192-4202
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Nathanson, Katherine L.|||0000-0002-6740-0901
Recurrence is a major cause of death among BRCA1/2 mutation carriers with breast (BrCa) and ovarian cancers (OvCa). Herein we perform multi-omic sequencing on 67 paired primary and recurrent BrCa and OvCa from 27 BRCA1/2 mutation carriers to identify potential recurrence-specific drivers. PARP1 amplifications are identified in recurrences (False Discovery Rate q = 0.05), and PARP1 is significantly overexpressed across primary BrCa and recurrent BrCa and OvCa, independent of amplification status. RNA sequencing analysis finds two BRCA2 isoforms, BRCA2-201/Long and BRCA2-001/Short, respectively predicted to be sensitive and insensitive to nonsense-mediated decay. BRCA2-001/Short is expressed more frequently in recurrences and associated with reduced overall survival in breast cancer (87 vs. 121 months; Hazard Ratio = 2.5 [1.18-5.5]). Loss of heterozygosity (LOH) status is discordant in 25% of patient's primary and recurrent tumors, with switching between both LOH and lack of LOH found. Our study reveals multiple potential drivers of recurrent disease in BRCA1/2 mutation-associated cancer, improving our understanding of tumor evolution and suggesting potential biomarkers. Carriers of pathogenic BRCA1/2 variants have a higher risk of breast and ovarian cancers, which recur frequently. Here, the authors sequence primary and recurrent tumours of BRCA1/2 mutation carriers, finding PARP1 amplifications, differential BRCA2 isoform usage, and discordant loss of heterozygosity that are associated with recurrence.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Bonache, Sandra|||0000-0002-7395-8143
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Carrasco, Estela|||0000-0003-1964-7675
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Montalban, Gemma|||0000-0002-6958-4759
  • Muñoz-Subirana, N.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lasa, Adriana|||0000-0001-9957-9646
  • Serra, Violeta|||0000-0001-6620-1065
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Surralles, Jordi|||0000-0002-4041-7519
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rp11-362k2.2:Rp11-767i20.1 genetic variation is associated with post-reperfusion therapy parenchymal hematoma. a gwas meta-analysis

  • Muiño, Elena|||0000-0001-5839-7328
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Carrera, Caty|||0000-0002-0804-0969
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cullell, Natalia|||0000-0001-5118-1014
  • Lledós, Miquel|||0000-0001-8832-789X
  • Castillo, J.
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Campos, Francisco|||0000-0001-8665-1039
  • Rodríguez-Castro, E.
  • Millán, M.
  • Muñoz-Narbona, Lucia|||0000-0002-0884-3024
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • López-Cancio, E.
  • Ribó, M.
  • Álvarez Sabín, José|||0000-0002-8054-9209
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • Soriano-Tárraga, C.
  • Vives-Bauza, C.
  • Diaz-Navarro, Rosa
  • Tur, Silvia
  • Obach, Víctor|||0000-0002-0518-1053
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Segura, T.
  • Serrano-Heras, G.
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Guisado-Alonso, Daniel|||0000-0002-5799-3184
  • Guasch Jiménez, Marina|||0000-0001-6024-8348
  • Marín-Bueno, Rebeca|||0000-0002-0354-6602
  • Martínez-Domeño, Alejandro|||0000-0002-9933-3192
  • Freijo-Guerrero, M.D.M.
  • Moniche, F.
  • Cabezas, Juan Antonio
  • Castellanos, M.
  • Krupinsky, J.
  • Strbian, D.
  • Tatlisumak, T.
  • Thijs, V.
  • Lemmens, R.
  • Slowik, Agnieszka
  • Pera, J.
  • Heitsch, Laura
  • Ibañez, Laura
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Dhar, R.
  • Lee, J.M.
  • Montaner, J.
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Stroke is one of the most common causes of death and disability. Reperfusion therapies are the only treatment available during the acute phase of stroke. Due to recent clinical trials, these therapies may increase their frequency of use by extending the time-window administration, which may lead to an increase in complications such as hemorrhagic transformation, with parenchymal hematoma (PH) being the more severe subtype, associated with higher mortality and disability rates. Our aim was to find genetic risk factors associated with PH, as that could provide molecular targets/pathways for their prevention/treatment and study its genetic correlations to find traits sharing genetic background. We performed a GWAS and meta-analysis, following standard quality controls and association analysis (fastGWAS), adjusting age, NIHSS, and principal components. FUMA was used to annotate, prioritize, visualize, and interpret the meta-analysis results. The total number of patients in the meta-analysis was 2034 (216 cases and 1818 controls). We found rs79770152 having a genome-wide significant association (beta 0.09, p-value 3.90 × 10) located in the RP11-362K2.2:RP11-767I20.1 gene and a suggestive variant (rs13297983: beta 0.07, p-value 6.10 × 10) located in PCSK5 associated with PH occurrence. The genetic correlation showed a shared genetic background of PH with Alzheimer's disease and white matter hyperintensities. In addition, genes containing the ten most significant associations have been related to aggregated amyloid-β, tau protein, white matter microstructure, inflammation, and matrix metalloproteinases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection

  • Ezeonwumelu, I.J.|||0000-0003-4007-2212
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Felip, Eudald|||0000-0002-3812-1313
  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Calba, Ignasi
  • Massanella, Marta|||0000-0002-3326-151X
  • Sirera, Guillem|||0000-0003-4014-9355
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
  • Badia, Roger|||0000-0003-3982-7577
HIV latent infection may be associated with disrupted viral RNA sensing, interferon (IFN) signaling, and/or IFN stimulating genes (ISG) activation. Here, we evaluated the use of compounds selectively targeting at the inhibitor of nuclear factor-κB (IκB) kinase (IKK) complex subunits and related kinases (TBK1) as a novel pathway to reverse HIV-1 latency in latently infected non-clonal lymphoid and myeloid cell in vitro models. IKK inhibitors (IKKis) triggered up to a 1.8-fold increase in HIV reactivation in both, myeloid and lymphoid cell models. The best-in-class IKKis, targeting TBK-1 (MRT67307) and IKKβ (TCPA-1) respectively, were also able to significantly induce viral reactivation in CD4+ T cells from people living with HIV (PLWH) ex vivo. More importantly, although none of the compounds tested showed antiviral activity, the combination of the distinct IKKis with ART did not affect the latency reactivation nor blockade of HIV infection by ART. Finally, as expected, IKKis did not upregulate cell activation markers in primary lymphocytes and innate immune signaling was blocked, resulting in downregulation of inflammatory cytokines. Overall, our results support a dual role of IKKis as immune modulators being able to tackle the HIV latent reservoir in lymphoid and myeloid cellular models and putatively control the hyperinflammatory responses in chronic HIV-1 infection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients

  • Solana, Elisabeth|||0000-0001-7973-2439
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Lopez-Soley, Elisabet
  • Radua, Joaquim|||0000-0003-1240-5438
  • Sola-Valls, Nuria
  • Montejo, Carmen
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Pulido-Valdeolivas, Irene|||0000-0003-0188-2458
  • Sepúlveda, Maria
  • Andorra, Magí
  • Berenguer, Juan|||0000-0001-8541-8200
  • Villoslada, P.|||0000-0002-8735-6119
  • Martinez-Lapiscina, E.H.
  • Prados Carrasco, Ferran|||0000-0002-7872-0142
  • Saiz, Albert|||0000-0002-5793-8791
  • Fortea, Juan|||0000-0002-1340-638X
  • Llufriu, Sara|||0000-0003-4273-9121
The spatio-temporal characteristics of grey matter (GM) impairment in multiple sclerosis (MS) are poorly understood. We used a new surface-based diffusion MRI processing tool to investigate regional modifications of microstructure, and we quantified volume loss in GM in a cohort of patients with MS classified into three groups according to disease duration. Additionally, we investigated the relationship between GM changes with disease severity. We studied 54 healthy controls and 247 MS patients classified regarding disease duration: MS1 (less than 5 years, n = 67); MS2 (5-15 years, n = 107); and MS3 (more than15 years, n = 73). We compared GM mean diffusivity (MD), fractional anisotropy (FA) and volume between groups, and estimated their clinical associations. Regional modifications in diffusion measures (MD and FA) and volume did not overlap early in the disease, and became widespread in later phases. We found higher MD in MS1 group, mainly in the temporal cortex, and volume reduction in deep GM and left precuneus. Additional MD changes were evident in cingulate and occipital cortices in the MS2 group, coupled to volume reductions in deep GM and parietal and frontal poles. Changes in MD and volume extended to more than 80% of regions in MS3 group. Conversely, increments in FA, with very low effect size, were observed in the parietal cortex and thalamus in MS1 and MS2 groups, and extended to the frontal lobe in the later group. MD and GM changes were associated with white matter lesion load and with physical and cognitive disability. Microstructural integrity loss and atrophy present differential spatial predominance early in MS and accrual over time, probably due to distinct pathogenic mechanisms that underlie tissue damage.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction

  • Duran-Castells, Clara|||0000-0002-4034-5738
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Kawana-Tachikawa, Ai|||0000-0002-3082-5324
  • Prats, Anna|||0000-0002-3586-4525
  • Martinez-Zalacain, Ignacio
  • Kobayashi-Ishihara, Mie|||0000-0001-6342-9451
  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Peña, Ruth
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Silva-Arrieta, Sandra
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Ballana, Ester|||0000-0002-5215-7363
  • Prado, Julia G.|||0000-0002-5439-4645
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Sanchez, Jorge
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Hartigan-O'Connor, Dennis
  • Wyss-Coray, Tony
  • Meyerhans, Andreas|||0000-0003-0620-5317
  • Gisslén, Magnus
  • Price, Richard W.
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Brander, Christian|||0000-0002-0548-5778
  • Ruiz Riol, Marta|||0000-0003-1899-8879
The implementation and access to combined antiretroviral treatment (cART) have dramatically improved the quality of life of people living with HIV (PLWH). However, some comorbidities, such as neurological disorders associated with HIV infection still represent a serious clinical challenge. Soluble factors in plasma that are associated with control of HIV replication and neurological dysfunction could serve as early biomarkers and as new therapeutic targets for this comorbidity. We used a customized antibody array for determination of blood plasma factors in 40 untreated PLWH with different levels of viremia and found sirtuin-2 (SIRT2), an NAD-dependent deacetylase, to be strongly associated with elevated viral loads and HIV provirus levels, as well as with markers of neurological damage (a-synuclein [SNCA], brain-derived neurotrophic factor [BDNF], microtubule-associated protein tau [MAPT], and neurofilament light protein [NFL]). Also, longitudinal analysis in HIV-infected individuals with immediate (n = 9) or delayed initiation (n = 10) of cART revealed that after 1 year on cART, SIRT2 plasma levels differed between both groups and correlated inversely with brain orbitofrontal cortex involution. Furthermore, targeting SIRT2 with specific small-molecule inhibitors in in vitro systems using J-LAT A2 and primary glial cells led to diminished HIV replication and virus reactivation from latency. Our data thus identify SIRT2 as a novel biomarker of uncontrolled HIV infection, with potential impact on neurological dysfunction and offers a new therapeutic target for HIV treatment and cure. IMPORTANCE Neurocognitive disorders are frequently reported in people living with HIV (PLWH) even with the introduction of combined antiretroviral treatment (cART). To identify biomarkers and potential therapeutic tools to target HIV infection in peripheral blood and in the central nervous system (CNS), plasma proteomics were applied in untreated chronic HIV-infected individuals with different levels of virus control. High plasma levels of sirtuin-2 (SIRT2), an NAD + deacetylase, were detected in uncontrolled HIV infection and were strongly associated with plasma viral load and proviral levels. In parallel, SIRT2 levels in the peripheral blood and CNS were associated with markers of neurological damage and brain involution and were more pronounced in individuals who initiated cART later in infection. In vitro infection experiments using specific SIRT2 inhibitors suggest that specific targeting of SIRT2 could offer new therapeutic treatment options for HIV infections and their associated neurological dysfunction.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Polygenic Risk Score Based on a Cardioembolic Stroke Multitrait Analysis Improves a Clinical Prediction Model for This Stroke Subtype

  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Muiño, Elena|||0000-0001-5839-7328
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cullell, Natalia|||0000-0001-5118-1014
  • Lledós, Miquel|||0000-0001-8832-789X
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Campos, Francisco|||0000-0001-8665-1039
  • Castillo, José
  • Freijo, Marimar
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Obach, Víctor|||0000-0002-0518-1053
  • Álvarez Sabín, José|||0000-0002-8054-9209
  • Molina, Carlos A.|||0000-0001-6058-6259
  • Ribo, Marc|||0000-0001-9242-043X
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Muñoz-Narbona, Lucia|||0000-0002-0884-3024
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Diaz-Navarro, Rosa
  • Vives-Bauza, Cristòfol
  • Serrano-Heras, Gemma|||0000-0001-9368-4832
  • Segura, Tomás|||0000-0003-3625-0987
  • Ibañez, Laura
  • Heitsch, Laura
  • Delgado, Pilar
  • Dhar, Rajat|||0000-0002-5167-5097
  • Krupinski, Jerzy|||0000-0002-5136-8898
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Blay, Natalia|||0000-0002-7160-8529
  • Sumoy, Lauro|||0000-0003-0005-4618
  • de Cid, Rafael|||0000-0003-3579-6777
  • Montaner, Joan|||0000-0003-4845-2279
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Lee, Jim-Moo
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Background: Occult atrial fibrillation (AF) is one of the major causes of embolic stroke of undetermined source (ESUS). Knowing the underlying etiology of an ESUS will reduce stroke recurrence and/or unnecessary use of anticoagulants. Understanding cardioembolic strokes (CES), whose main cause is AF, will provide tools to select patients who would benefit from anticoagulants among those with ESUS or AF. We aimed to discover novel loci associated with CES and create a polygenetic risk score (PRS) for a more efficient CES risk stratification. Methods: Multitrait analysis of GWAS (MTAG) was performed with MEGASTROKE-CES cohort (n = 362,661) and AF cohort (n = 1,030,836). We considered significant variants and replicated those variants with MTAG p-value < 5 × 10 influencing both traits (GWAS-pairwise) with a p-value < 0.05 in the original GWAS and in an independent cohort (n = 9,105). The PRS was created with PRSice-2 and evaluated in the independent cohort. Results: We found and replicated eleven loci associated with CES. Eight were novel loci. Seven of them had been previously associated with AF, namely, CAV1, ESR2, GORAB, IGF1R, NEURL1, WIPF1, and ZEB2. KIAA1755 locus had never been associated with CES/AF, leading its index variant to a missense change (R1045W). The PRS generated has been significantly associated with CES improving discrimination and patient reclassification of a model with age, sex, and hypertension. Conclusion: The loci found significantly associated with CES in the MTAG, together with the creation of a PRS that improves the predictive clinical models of CES, might help guide future clinical trials of anticoagulant therapy in patients with ESUS or AF.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation

  • Koehorst, Emma
  • Odria, Renato|||0000-0002-3420-797X
  • Capó, Júlia
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Arbex, Andrea|||0000-0002-3741-4755
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Linares-Pardo, Ian
  • Natera de Benito, Daniel
  • Saez, Verónica
  • Nascimento, Andrés
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Rubio, Miguel Ángel|||0000-0003-0735-6854
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Rodríguez-Palmero, Agustí|||0000-0002-4141-5515
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Nogales, Gisela|||0000-0002-7414-212X
  • Suelves Esteban, Mònica|||0000-0001-7095-5804
Myotonic dystrophy type 1 (DM1) is a progressive, non-treatable, multi-systemic disorder. To investigate the contribution of epigenetics to the complexity of DM1, we compared DNA methy-lation profiles of four annotated CpG islands (CpGis) in the DMPK locus and neighbouring genes, in distinct DM1 tissues and derived cells, representing six DM1 subtypes, by bisulphite sequencing. In blood, we found no differences in CpGi 74, 43 and 36 in DNA methylation profile. In contrast, a CTCF1 DNA methylation gradient was found with 100% methylation in congenital cases, 50% in childhood cases and 13% in juvenile cases. CTCF1 methylation correlated to disease severity and CTG expansion size. Notably, 50% of CTCF1 methylated cases showed methylation in the CTCF2 regions. Additionally, methylation was associated with maternal transmission. Interestingly, the evaluation of seven families showed that unmethylated mothers passed on an expansion of the CTG repeat, whereas the methylated mothers transmitted a contraction. The analysis of patient-derived cells showed that DNA methylation profiles were highly preserved, validating their use as faithful DM1 cellular models. Importantly, the comparison of DNA methylation levels of distinct DM1 tissues revealed a novel muscle-specific epigenetic signature with methylation of the CTCF1 region accompanied by demethylation of CpGi 43, a region containing an alternative DMPK promoter, which may decrease the canonical promoter activity. Altogether, our results showed a distinct DNA methylation profile across DM1 tissues and uncovered a novel and dual epigenetic signature in DM1 muscle samples, providing novel insights into the epigenetic changes associated with DM1.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Peripheral immune aberrations in fibromyalgia, a systematic review, meta-analysis and meta-regression

  • Andrés Rodríguez, Laura|||0000-0001-5133-9811
  • Borràs, Xavier|||0000-0003-3972-1385
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Pérez-Aranda, Adrián|||0000-0002-1602-3413
  • Angarita-Osorio, Natalia|||0000-0001-8925-2754
  • Moreno-Peral, Patricia|||0000-0003-4130-9090
  • Montero-Marín, Jesús|||0000-0001-5677-1662
  • Garcia-Campayo, Javier|||0000-0002-3797-4218
  • Carvalho, André F.
  • Maes, Michael|||0000-0002-2012-871X
  • Luciano, Juan Vicente|||0000-0003-0750-1599
The objective was to identify immune alterations in patients with fibromyalgia syndrome (FMS) compared to healthy controls (HC) using meta-analysis and meta-regression. Six electronic databases were searched for suitable original articles investigating immune biomarkers in FMS in comparison to HC. We extracted outcomes and variables of interest, such as mean and SD of peripheral blood immune biomarkers, age or sex. A random-effects model with restricted maximum-likelihood estimator was used to compute effect sizes (standardized mean difference and 95% CI, Hedges' g) and meta-analysis, group meta-analysis and meta-regressions were conducted. Forty-three papers were included in this systematic review, of which 29 were suitable for meta-analysis. Interleukin (IL)-6 (g = 0.36 (0.09-0.63); I2 = 85.94; p = 0.01), IL-4 (g = 0.50 (0.03-0.98); I2 = 81.87; p = 0.04), and IL-17A (g = 0.53 (0.00-1.06); I2 = 87.15; p = 0.05), were significantly higher in FMS compared to HC while also combinations of cytokines into relevant phenotypes were significantly upregulated including M1 macrophage (g = 0.23 (0.03-0.43); I2 = 77.62; p = 0.02), and immune-regulatory (g = 0.40 (0.09-0.72); I2 = 84.81; p = 0.01) phenotypes. Heterogeneity levels were very high and subgroup and meta-regression analyses showed that many covariates explained part of the heterogeneity including medication washout, sex, time of blood sampling and exclusion of patients with major depressive disorder. In conclusion, FMS is accompanied by a disbalance between upregulated pro-inflammatory (M1 and Th-17) and immune-regulatory cytokines although effect sizes are small-to-moderate. Based on our results we provide specific methodological suggestions for future research, which should assess Th-1, Th-17, chemokines, and Th-2 phenotypes while controlling for possible confounding variables specified in this study.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of Potential Muscle Biomarkers in McArdle Disease, Insights from Muscle Proteome Analysis

  • García-Consuegra, Inés
  • Asensio-Peña, Sara|||0000-0002-2048-5899
  • Garrido-Moraga, Rocío|||0000-0002-2856-4399
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Santalla, Alfredo|||0000-0001-9418-0564
  • Nogales, Gisela|||0000-0002-7414-212X
  • Serrano-Lorenzo, Pablo|||0000-0002-5661-7574
  • Andreu Périz, Antoni Lluís
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Zugaza, José L.|||0000-0002-9000-6398
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Martín, Miguel A.|||0000-0003-4741-772X
Glycogen storage disease type V (GSDV, McArdle disease) is a rare genetic myopathy caused by deficiency of the muscle isoform of glycogen phosphorylase (PYGM). This results in a block in the use of muscle glycogen as an energetic substrate, with subsequent exercise intolerance. The pathobiology of GSDV is still not fully understood, especially with regard to some features such as persistent muscle damage (i.e., even without prior exercise). We aimed at identifying potential muscle protein biomarkers of GSDV by analyzing the muscle proteome and the molecular networks associated with muscle dysfunction in these patients. Muscle biopsies from eight patients and eight healthy controls showing none of the features of McArdle disease, such as frequent contractures and persistent muscle damage, were studied by quantitative protein expression using isobaric tags for relative and absolute quantitation (iTRAQ) followed by artificial neuronal networks (ANNs) and topology analysis. Protein candidate validation was performed by Western blot. Several proteins predominantly involved in the process of muscle contraction and/or calcium homeostasis, such as myosin, sarcoplasmic/endoplasmic reticulum calcium ATPase 1, tropomyosin alpha-1 chain, troponin isoforms, and alpha-actinin-3, showed significantly lower expression levels in the muscle of GSDV patients. These proteins could be potential biomarkers of the persistent muscle damage in the absence of prior exertion reported in GSDV patients. Further studies are needed to elucidate the molecular mechanisms by which PYGM controls the expression of these proteins.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma Amino Acid Concentrations in Patients with Alcohol and/or Cocaine Use Disorders and Their Association with Psychiatric Comorbidity and Sex

  • García Marchena, Nuria|||0000-0002-0575-3613
  • Marcos, Alberto
  • Flores-López, María|||0000-0003-3489-1465
  • Moreno-Fernández, Mario
  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Porras-Perales, Oscar
  • Torres-Galván, Sandra
  • Araos, Pedro|||0000-0001-5172-8796
  • Serrano, Antonia
  • Muga, Roberto|||0000-0001-6301-431X
  • Ruiz-Ruiz, Juan Jesús|||0000-0001-8692-4463
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Ambrosio, Emilio
  • Pavón-Morón, Francisco Javier|||0000-0002-5256-8904
(1) Background: Co-occurrence of mental and substance use disorders (SUD) is prevalent, but complicates their clinical courses, and specific biomarkers are required. Amino acids are altered in primary mental disorders; however, little is known about SUD and psychiatric comorbidity. Because most psychiatric disorders and biomarkers show sex differences, we investigated amino acids in men and women with alcohol and/or cocaine use disorders (AUD and/or CUD) and psychiatric comorbidity. (2) Methods: A cross-sectional study was conducted in 295 participants, who were divided into four groups (AUD, n = 60; CUD, n = 41; AUD + CUD, n = 64; and control, n = 130). Participants were clinically assessed, and plasma amino acid concentrations were analyzed in relation to sex, diagnosis of SUD and psychiatric comorbidity (3) Results: In the total sample, there were sex differences, and women showed lower Iso, Leu, Gln and Glu than men. While patients with CUD and AUD + CUD had higher Glu, Gly, Orn and Ser than controls, patients with AUD showed no differences. In SUD, patients with psychiatric comorbidity had lower Orn and higher Ala than non-comorbid patients in the AUD group. (4) Conclusions: There was a dysregulation of plasma amino acids in abstinent patients with SUD. However, our results suggest the importance of considering the clinical characteristics and sex in the validity of amino acids as potential biomarkers for SUD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SARS-CoV-2 Infection Modulates ACE2 Function and Subsequent Inflammatory Responses in Swabs and Plasma of COVID-19 Patients

  • Gutiérrez-Chamorro, Lucía|||0000-0002-7649-951X
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Barrios, Clara|||0000-0003-0492-4107
  • Palau, Vanesa|||0000-0002-3210-7924
  • Nevot Banús, Maria|||0000-0003-4947-4648
  • Pedreño-López, Sònia|||0000-0002-1919-3530
  • Senserrich, Jordi|||0000-0002-8021-1718
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Cabrera Navarro, Cecilia|||0000-0002-9941-6828
  • Mitjà, Oriol|||0000-0003-3266-8868
  • Crespo, Marta|||0000-0001-6992-6379
  • Pascual, Julio|||0000-0002-4735-7838
  • Riera Oliva, Marta|||0000-0003-4362-7965
  • Ballana, Ester|||0000-0002-5215-7363
Angiotensin converting enzyme 2 (ACE2) is a host ectopeptidase and the receptor for the SARS-CoV-2 virus, albeit virus-ACE2 interaction goes far beyond viral entry into target cells. Controversial data exists linking viral infection to changes in ACE2 expression and function, which might influence the subsequent induction of an inflammatory response. Here, we tested the significance of soluble ACE2 enzymatic activity longitudinally in nasopharyngeal swabs and plasma samples of SARS-CoV-2 infected patients, along with the induction of inflammatory cytokines. Release of soluble functional ACE2 increases upon SARS-CoV-2 infection in swabs and plasma of infected patients, albeit rapidly decreasing during infection course in parallel with ACE2 gene expression. Similarly, SARS-CoV-2 infection also induced the expression of inflammatory cytokines. These changes positively correlated with the viral load. Overall, our results demonstrate the existence of mechanisms by which SARS-CoV-2 modulates ACE2 expression and function, intracellular viral sensing and subsequent inflammatory response, offering new insights into ACE2 dynamics in the human upper respiratory tract and pointing towards soluble ACE2 levels as a putative early biomarker of infection severity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effectiveness of a Multicomponent Treatment Based on Pain Neuroscience Education, Therapeutic Exercise, Cognitive Behavioral Therapy, and Mindfulness in Patients With Fibromyalgia (FIBROWALK Study), A Randomized Controlled Trial

  • Serrat López, Mayte|||0000-0002-5591-9407
  • Sanabria-Mazo, Juan P.|||0000-0003-1688-435X
  • Almirall, Míriam|||0000-0002-4874-8013
  • Musté, Marta|||0000-0002-0748-1121
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Méndez Ulrich, Jorge Luis|||0000-0001-9718-0607
  • Sanz Ruiz, Antoni|||0000-0002-7952-4477
  • Luciano, Juan Vicente|||0000-0003-0750-1599
Objective. The purpose of this study was to evaluate the effectiveness of a 12-week multicomponent treatment based on pain neuroscience education, therapeutic exercise, cognitive behavioral therapy, and mindfulness-in addition to treatment as usual-compared with treatment as usual only in patients with fibromyalgia. Methods. This randomized controlled trial involved a total of 272 patients who were randomly assigned to either multicomponent treatment (n = 135) or treatment as usual (n = 137). The multicomponent treatment (2-hour weekly sessions) was delivered in groups of 20 participants. Treatment as usual was mainly based on pharmacological treatment according to the predominant symptoms. Data on functional impairment using the Revised Fibromyalgia Impact Questionnaire as the primary outcome were collected as were data for pain, fatigue, kinesiophobia, physical function, anxiety, and depressive symptoms (secondary outcomes) at baseline, 12 weeks, and, for the multicomponent group only, 6 and 9 months. An intention-to-treat approach was used to analyze between-group differences. Baseline differences between responders (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Does practice make perfect?, functional connectivity of the salience network and somatosensory network predicts response to mind-body treatments for fibromyalgia

  • Medina, Sonia|||0000-0001-8883-6520
  • O'Daly, Owen G.|||0000-0001-5690-1252
  • Howard, Matthew A.|||0000-0002-9359-3057
  • Feliu-Soler, Albert|||0000-0003-2810-7670
  • Luciano, Juan Vicente|||0000-0003-0750-1599
BACKGROUND: Mind-body treatments can improve coping mechanisms to deal with pain, improve the quality of life of patients with fibromyalgia syndrome (FMS), and reduce perceived pain in some cases. However, responses to these treatments are highly variable, the mechanisms underpinning them remain unclear, and reliable predictors of treatment response are lacking. We employed resting-state blood oxygen level-dependent (rsBOLD) functional magnetic resonance imaging (fMRI) to examine changes in brain functional connectivity (FC) following mind-body treatment that may relate to and predict pain relief. METHODS: We recruited patients with FMS who underwent either mindfulness-based stress reduction (MBSR; n = 18) or a psychoeducational program (FibroQoL; n = 22) and a treatment-as-usual FMS group (TAU; n = 18). We collected rsBOLD data, alongside subjective pain, anxiety, depression, and catastrophizing measures prior to and following treatments. We examined behavioral changes and FC changes in the salience network (SN) and sensorimotor network (SMN) and performed regression analyses to identify predictors for treatment response. RESULTS: The MBSR and FibroQoL groups experienced significant reductions in pain catastrophizing. After treatment, the FC of the sensorimotor cortex with the rest of the SMN became significantly reduced in the MBSR group compared to the TAU group. The FC between the SN and the SMN at baseline was negatively correlated with pain reductions following MBSR but positively correlated with pain reductions in the FibroQoL group. These results yielded large to very large effect sizes. Following MBSR, only for those patients with lower baseline SMN-SN FC, minutes of mindfulness practice were positively associated with clinical improvement (small to medium effect size). CONCLUSIONS: Different mind-body treatments are underpinned by discrete brain networks. Measures of the functional interplay between SN and SMN have the potential as predictors of mind-body treatment response in patients with FMS.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel
  • Palafox Sánchez, Marta
  • Scaltriti, Maurizio
  • Razavi, Pedram
  • Arribas López, Joaquin Vicente
  • Serra Elizalde, Violeta
  • Gris Oliver, Albert
  • Bellet Ezquerra, Meritxell
Biomarcadores de respuesta a fármacos; Redes de co-ocurrencia de conductores; Oncología de precisión, Biomarcadors de resposta a fàrmacs; Xarxes de co-ocurrència de conductors; Oncologia de precisió, Drug-response biomarkers; Driver co-occurrence networks; Precision oncology, Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients’ progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling., L.M. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the Generalitat de Catalunya (VEIS 001-P-001). V.S. is a recipient of a Miguel Servet grant from ISCIII (CPII19/00033) and receives funds from AGAUR (2017 SGR 540). The PDX program is supported by a GHD-Pink (FERO foundation) grant to V.S., A.G.-O. and M.P. received a FI-AGAUR and a Juan de la Cierva (MJCI-2015-25412) fellowship, respectively. M.S., P.R., and S.C. acknowledge the support of the NIH grants P30 CA008748, RO1CA190642, and the Breast Cancer Research Foundation. Additionally, P.R. receives funds from the Breast Cancer Alliance.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder

  • Moreno‑Alcázar, Ana
  • Ribases Haro, Marta
  • Sanchez Mora, Cristina P
  • Palomar Martínez, Gloria
  • Bosch Munso, Rosa M
  • Casas Brugué, Miquel
  • Ramos-Quiroga, Josep Antoni
TDAH; Genotipatge; Imatges per ressonància magnètica, TDAH; Genotipado; Imagen de resonancia magnética, ADHD; Genotyping; Magnetic resonance imaging, Previous studies have shown that the gene encoding the adhesion G protein-coupled receptor L3 (ADGRL3; formerly latrophilin 3, LPHN3) is associated with Attention-Deficit/Hyperactivity Disorder (ADHD). Conversely, no studies have investigated the anatomical or functional brain substrates of ADGRL3 risk variants. We examined here whether individuals with different ADGRL3 haplotypes, including both patients with ADHD and healthy controls, showed differences in brain anatomy and function. We recruited and genotyped adult patients with combined type ADHD and healthy controls to achieve a sample balanced for age, sex, premorbid IQ, and three ADGRL3 haplotype groups (risk, protective, and others). The final sample (n = 128) underwent structural and functional brain imaging (voxel-based morphometry and n-back working memory fMRI). We analyzed the brain structural and functional effects of ADHD, haplotypes, and their interaction, covarying for age, sex, and medication. Individuals (patients or controls) with the protective haplotype showed strong, widespread hypo-activation in the frontal cortex extending to inferior temporal and fusiform gyri. Individuals (patients or controls) with the risk haplotype also showed hypo-activation, more focused in the right temporal cortex. Patients showed parietal hyper-activation. Disorder-haplotype interactions, as well as structural findings, were not statistically significant. To sum up, both protective and risk ADGRL3 haplotypes are associated with substantial brain hypo-activation during working memory tasks, stressing this gene’s relevance in cognitive brain function. Conversely, we did not find brain effects of the interactions between adult ADHD and ADGRL3 haplotypes., This work was supported by several grants from the Plan Nacional de I+D+i and co-funded by the Instituto de Salud Carlos III-Subdirección General de Evaluación y Fomento de la Investigación and the European Regional Development Fund (FEDER): Research Project Grant (PI11/01629, PI11/01766, PI16/01505, PI17/00289, PI18/01788, PI19/00394, PI19/00721, and PI19/01224), Miguel Servet Research Contracts (CP09/00119 and CPII15/00023 to MR, CP10/00596 to EP-C and CP14/00041 and CPII19/00009 to JR), Sara Borrell contract (CD15/00199 to CSM), PFIS contract (FI20/00047 to LF), mobility grant (MV16/00039 to CSM), Pla Estratègic de Recerca i Innovació en Salut (PERIS); Generalitat de Catalunya (MENTAL-Cat; SLT006/17/287) and the Agència de Gestió d’Ajuts Universitaris i de Recerca-AGAUR, Catalonian Government (2009SGR211 and 2017SGR1461). The funding organizations played no role in the study design, data collection and analysis, or manuscript approval.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

  • Shah, Jennifer
  • Pueschl, Dana
  • Wubbenhorst, Bradley
  • Fan, Mengyao
  • Pluta, John
  • D’Andrea, Kurt
  • Llop Guevara, Alba
  • Serra Elizalde, Violeta
  • Balmaña Gelpí, Judith
Breast cancer; Cancer genetics; RNA sequencing, Cáncer de mama; Genética del cáncer; Secuenciación de ARN, Càncer de mama; Genètica del càncer; Seqüenciació d'ARN, Recurrence is a major cause of death among BRCA1/2 mutation carriers with breast (BrCa) and ovarian cancers (OvCa). Herein we perform multi-omic sequencing on 67 paired primary and recurrent BrCa and OvCa from 27 BRCA1/2 mutation carriers to identify potential recurrence-specific drivers. PARP1 amplifications are identified in recurrences (False Discovery Rate q = 0.05), and PARP1 is significantly overexpressed across primary BrCa and recurrent BrCa and OvCa, independent of amplification status. RNA sequencing analysis finds two BRCA2 isoforms, BRCA2-201/Long and BRCA2-001/Short, respectively predicted to be sensitive and insensitive to nonsense-mediated decay. BRCA2-001/Short is expressed more frequently in recurrences and associated with reduced overall survival in breast cancer (87 vs. 121 months; Hazard Ratio = 2.5 [1.18–5.5]). Loss of heterozygosity (LOH) status is discordant in 25% of patient’s primary and recurrent tumors, with switching between both LOH and lack of LOH found. Our study reveals multiple potential drivers of recurrent disease in BRCA1/2 mutation-associated cancer, improving our understanding of tumor evolution and suggesting potential biomarkers., This work was supported by the Tumor Tissue and Biospecimen Bank and the Next Generation Sequencing Core at the University of Pennsylvania (and in particular, we appreciated the help of Dr. Jonathan Schug). We would also like to thank Akoya Biosciences for their technical expertize regarding CODEX analyses. Lastly, the RNA sequencing pipeline used for this study was based on content from Dr. Dan Beiting’s DIY Transcriptomics class at the University of Pennsylvania (Spring 2021), for which we thank him as well. Figure 6 and Supplementary Fig. 15 were created using a licensed version of BioRender. This work was supported by the Basser Center for BRCA at the University of Pennsylvania (S.M.D., K.L.N.), the Gray Foundation Team Science Award (K.L.N.), the V Foundation for Cancer Research BRCA1/2 Convergence Team Award (K.L.N.), the Breast Cancer Research Foundation (S.M.D., K.L.N.) T32 HG009495 (A.K.), Miguel Servet Program (ISCIII) [CPII19/00033] (V.S.) and Asociación Española Contra el Cáncer (A.L.G.).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

  • Rodriguez, María Jimena
  • Perrone, María Cecilia
  • Riggio, Marina
  • Palafox Sánchez, Marta
  • Salinas, Valeria
  • Elia, Andres
  • Serra Elizalde, Violeta
Cancer; Cell biology, Càncer; Biologia cel·lular, Cáncer; Biología celular, Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, highlighting the need for novel therapeutic strategies to delay disease progression and improve patient survival. Here, we assessed the mechanisms of acquired resistance using T47D and MCF-7 tamoxifen- and palbociclib-resistant cell-line variants in culture and as xenografts, and patient-derived cells (PDCs) obtained from sensitive or resistant patient-derived xenografts (PDXs). In these models, we analyzed the effect of specific kinase inhibitors on survival, signaling and cellular aggressiveness. Our results revealed that mTOR inhibition is more effective than PI3K inhibition in overcoming resistance, irrespective of PIK3CA mutation status, by decreasing cell proliferation and tumor growth, as well as reducing cell migration and stemness. Moreover, a combination of mTOR and CDK4/6 inhibitors may prevent pathway reactivation downstream of PI3K, interfering with the survival of resistant cells and consequent tumor escape. In conclusion, we highlight the benefits of incorporating mTOR inhibitors into the current therapy in ER + breast cancer. This alternative therapeutic strategy not only enhances the antitumor response but may also delay the emergence of resistance and tumor recurrence., This work was supported by CONICET, ANPCYT (Grants PICT2509 & PICT0345), Instituto Nacional del Cáncer (Grants 2016 & 2018), Fundación Williams, Fundación Bunge & Born (Oster Grant) (Argentina); Instituto de Salud Carlos III (Grants PI20/00892 & CPII19/0033), Ministerio de Economía y Competitividad (FJCI-2015-25412) (Spain).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

  • Yndestad, Synnøve
  • Engebrethsen, Christina
  • Nikolaienko, Oleksii
  • Vintermyr, Olav Karsten
  • Lillestøl, Reidun
  • Llop-Guevara, Alba
  • Herencia Ropero, Andrea
  • Serra, Violeta
Homologous recombination; Primary breast cancer, Recombinació homòloga; Càncer de mama primari, Recombinación homóloga; Cáncer de mama primario, PURPOSE Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to assess the potential for PARPi in a wider group of patients with breast cancer. METHODS HRD status was established using targeted gene panel sequencing (360 genes) and BRCA1 methylation analysis of pretreatment biopsies from 201 patients with primary breast cancer in the phase II PETREMAC trial (ClinicalTrials.gov identifier: NCT02624973). HRD was defined as mutations in BRCA1, BRCA2, BRIP1, BARD1, or PALB2 and/or promoter methylation of BRCA1 (strict definition; HRD-S). In secondary analyses, a wider definition (HRD-W) was used, examining mutations in 20 additional genes. Furthermore, tumor BRCAness (multiplex ligation-dependent probe amplification), PAM50 subtyping, RAD51 nuclear foci to test functional HRD, tumor-infiltrating lymphocyte (TIL), and PD-L1 analyses were performed. RESULTS HRD-S was present in 5% of non-TNBC cases (n = 9 of 169), contrasting 47% of the TNBC tumors (n = 15 of 32). HRD-W was observed in 23% of non-TNBC (n = 39 of 169) and 59% of TNBC cases (n = 19 of 32). Of 58 non-TNBC and 30 TNBC biopsies examined for RAD51 foci, 4 of 4 (100%) non-TNBC and 13 of 14 (93%) TNBC cases classified as HRD-S had RAD51 low scores. In contrast, 4 of 17 (24%) non-TNBC and 15 of 19 (79%) TNBC biopsies classified as HRD-W exhibited RAD51 low scores. Of nine non-TNBC tumors with HRD-S status, only one had a basal-like PAM50 signature. There was a high concordance between HRD-S and either BRCAness, high TIL density, or high PD-L1 expression (each P < .001). CONCLUSION The prevalence of HRD in non-TNBC suggests that therapy targeting HRD should be evaluated in a wider breast cancer patient population. Strict HRD criteria should be implemented to increase diagnostic precision with respect to functional HRD., Supported by unrestricted grants from The K.G. Jebsen Foundation [SKGJ-MED-020 to H.P.E., S.K., P.E.L.], Helse Vest [912008 to P.E.L.], The Norwegian Research Council [273354 to P.E.L.] and The Norwegian Cancer Society [190281-2017 to S.K., 190275-2017 to P.E.L.]. Research funding was provided by Grieg Foundation (to H.P.E. and T.A.), Helse Vest [912252; Clinical researcher fellowship to H.P.E.], Generalitat de Catalunya [PERIS, SLT017/20/000081 to A.H.R.], “la Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 [LCF/TR/CC19/52470003 to A.L.G.], Asociación Española Contra el Cáncer [AECC, INVES20095LLOP to A.L.G.], Generalitat de Catalunya (PERIS Fellowship SLT002/16/00477 to A.L.G.) ERA PerMed [2019-215 to V.S.] and Miguel Servet fellowship (CPII19/00033 to V.S.). Additional funding and study medication was provided by Illumina [grant number 9529854], Pfizer [WI206347] and AstraZeneca [ESR-14-10077] to H.P.E., S.K., P.E.L.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

  • Ring, Alistair
  • Kilburn, Lucy
  • Pearson, Alex
  • Moretti, Laura
  • Afshari-Mehr, Angelica
  • Wardley, Andrew
  • Llop Guevara, Alba
  • Serra, Violeta
Olaparib; Ceralasertib; Triple-negative advanced breast cancer, Olaparib; Ceralasertib; Càncer de mama avançat triple negatiu, Olaparib; Ceralasertib; Cáncer de mama avanzado triple negativo, Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous replication stress and thereby increase sensitivity to inhibitors of ataxia telangiectasia and Rad3-related (ATR) protein. This phase II study examined the activity of the combination of PARP inhibitor, olaparib, and ATR inhibitor, ceralasertib (AZD6738), in patients with advanced TNBC. Patients and Methods: Patients with TNBC on most recent biopsy who had received 1 or 2 lines of chemotherapy for advanced disease or had relapsed within 12 months of (neo)adjuvant chemotherapy were eligible. Treatment was olaparib 300 mg twice a day continuously and celarasertib 160 mg on days 1–7 on a 28-day cycle until disease progression. The primary endpoint was confirmed objective response rate (ORR). Tissue and plasma biomarker analyses were preplanned to identify predictors of response. Results: 70 evaluable patients were enrolled. Germline BRCA1/2 mutations were present in 10 (14%) patients and 3 (4%) patients had somatic BRCA mutations. The confirmed ORR was 12/70; 17.1% (95% confidence interval, 10.4–25.5). Responses were observed in patients without germline or somatic BRCA1/2 mutations, including patients with mutations in other homologous recombination repair genes and tumors with functional homologous recombination deficiency by RAD51 foci. Conclusions: The response rate to olaparib and ceralasertib did not meet prespecified criteria for activity in the overall evaluable population, but responses were observed in patients who would not be expected to respond to olaparib monotherapy., This research was funded by the Stand Up to Cancer Campaign for Cancer Research UK (CRUK/15/010, C30746/A19505; to S. Martin, H. Johnson, L. Moretti) with additional support from AstraZeneca, Guardant Health, Bio-Rad and Asociación Española Contra el Cáncer (AECC, INVES20095LLOP; to A. Llop-Guevara). The ICR Clinical Trials and Statistics Unit is supported by the Cancer Research UK core programme grant (C1491/A25351; to L.S. Kilburn). This study represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, London, UK. In addition, plasmaMATCH is supported by the NIHR Manchester Clinical Research Facility at the Christie Hospital, Manchester, UK, the NIHR UCLH Clinical Research Facility at University College London Hospitals NHS Foundation Trust, London, UK, the Cancer Research UK Cambridge Centre, Cambridge Biomedical Research Centre (BRC-1215–20014) and Cambridge Experimental Cancer Medicine Centre, Cambridge, UK. The RAD51 analysis was supported with grants from the Spanish Association of Cancer Research and Instituto de Salud Carlos III (ERAPERMED2019–215, CPII19/00033, and INVES20095LLOP). plasmaMATCH is supported at participating sites in England by the NIHR Clinical Research Network, in Scotland by the Chief Scientist Office, and in Wales by Health and Care Research Wales.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

  • Carreira, Suzanne
  • Porta, Nuria
  • Arce Gallego, Sara
  • Llop Guevara, Alba
  • Bianchini, Diletta
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Seed, George
Pròstata; PARP; Biomarcadors, Próstata; PARP; Biomarcadores, Prostate; PARP; biomarkers, PARP inhibitors are approved for treating advanced prostate cancers (APCs) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B Phase II clinical trial samples, evaluating whole exome and low-pass whole genome sequencing and immunohistochemical assays evaluating ATM and RAD51 foci (testing homologous recombination repair function). BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA deletion. Biallelic, but not mono-allelic, PALB2 deleterious alterations were associated with clinical benefit. In the ATM cohort, loss of ATM protein by immunohistochemistry associated with better outcome. RAD51 foci loss identified tumors with biallelic BRCA and PALB2 alteration while most ATM- and CDK12-altered APCs had higher RAD51 foci levels. Overall, APCs with homozygous BRCA2 deletion are exceptional responders; PALB2 biallelic loss and loss of ATM immunohistochemical expression associated with clinical benefit., TOPARP is an investigator-initiated trial; we are grateful for the support and funding from AstraZeneca, and for the study grants from Cancer Research UK (CRUK/11/029; C12540/A12829; C12540/A13230; C12540/A20447). ICR-CTSU also receives program grant funding from Cancer Research UK (Grant number: C1491/A15955, C1491/A25351). We acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence (CEO13_2-002), the Prostate Cancer Foundation, and the UK Department of Health through an Experimental Cancer Medicine Centre (ECMC) grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Pasquale Rescigno was supported by a PCF Young Investigator Award 19YOUN19. The authors affiliated to VHIO acknowledge funding from “La Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 (LCF/TR/CC19/52470003), Fundacion FERO and Fundacion Cellex. J. Mateo, A. Llop-Guevara and V. Serra received grants from Fundacion Cientifica AECC (LABAE16020PORTT) and an ERAPERMED2019-215. J. Mateo gratefully acknowledges funding from the European Union’s Horizon 2020 research and innovation program (Marie Skłodowska-Curie grant 837900), Instituto de Salud Carlos III (Grant PI18/01384), Fundación AECC, CRIS Cancer Foundation and the US Department of Defense CDMRP (Impact Award PC170510P1). S. Arce-Gallego Research. Downloaded from cancerdiscovery.aacrjournals.org on July 1, 2021. © 2021 American Association for Cancer Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 27, 2021; DOI: 10.1158/2159-8290.CD-21-0007 3 and V. Serra were supported by Instituto de Salud Carlos III (FI19/00280, CPII19/00033).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours

  • Groelly, Florian
  • Porru, Manuela
  • Zimmer, Jutta
  • Benainous, Hugo
  • De Visser, Yanti
  • Kosova, Anastasiya
  • Serra Elizalde, Violeta
BRCA2; DNA damage responses; Pyridostatin, BRCA2; Respostes al dany de l'ADN; Piridostatina, BRCA2; Respuestas al daño del ADN; Piridotatina, The cells with compromised BRCA1 or BRCA2 (BRCA1/2) function accumulate stalled replication forks, which leads to replication-associated DNA damage and genomic instability, a signature of BRCA1/2-mutated tumours. Targeted therapies against BRCA1/2-mutated tumours exploit this vulnerability by introducing additional DNA lesions. Because homologous recombination (HR) repair is abrogated in the absence of BRCA1 or BRCA2, these lesions are specifically lethal to tumour cells, but not to the healthy tissue. Ligands that bind and stabilise G-quadruplexes (G4s) have recently emerged as a class of compounds that selectively eliminate the cells and tumours lacking BRCA1 or BRCA2. Pyridostatin is a small molecule that binds G4s and is specifically toxic to BRCA1/2-deficient cells in vitro. However, its in vivo potential has not yet been evaluated. Here, we demonstrate that pyridostatin exhibits a high specific activity against BRCA1/2-deficient tumours, including patient-derived xenograft tumours that have acquired PARP inhibitor (PARPi) resistance. Mechanistically, we demonstrate that pyridostatin disrupts replication leading to DNA double-stranded breaks (DSBs) that can be repaired in the absence of BRCA1/2 by canonical non-homologous end joining (C-NHEJ). Consistent with this, chemical inhibitors of DNA-PKcs, a core component of C-NHEJ kinase activity, act synergistically with pyridostatin in eliminating BRCA1/2-deficient cells and tumours. Furthermore, we demonstrate that pyridostatin triggers cGAS/STING-dependent innate immune responses when BRCA1 or BRCA2 is abrogated. Paclitaxel, a drug routinely used in cancer chemotherapy, potentiates the in vivo toxicity of pyridostatin. Overall, our results demonstrate that pyridostatin is a compound suitable for further therapeutic development, alone or in combination with paclitaxel and DNA-PKcs inhibitors, for the benefit of cancer patients carrying BRCA1/2 mutations., Research in A.B. laboratory is supported by grants of Italian Association for Cancer Research (AIRC # 21579), Ministry of Health (CO 2019-12369662) and from IRCCS-Regina Elena Cancer Institute. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 722729 (F.J.G.). Research in M.T. laboratory is supported by Cancer Research UK (DRCPGM\100001), Medical Research Council and University of Oxford. A.R. received support from the UK Medical Research Council grant MC_PC_12006. V.S. received support from Instituto de Salud Carlos III (CPII19/00033, PI17/01080), GHD pink and the FERO Foundation.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test

  • Kramer, Claire
  • Yaniz-Galende, Elisa
  • Pellegrino, Benedetta
  • ter Haar, Natalja
  • Llop-Guevara, Alba
  • Herencia Ropero, Andrea
  • Serra, Violeta
Biomarker; High-hrade serous ovarian carcinoma; Homologous recombination deficiency, Biomarcador; Carcinoma de ovario seroso de alto grado; Deficiencia de recombinación homóloga, Biomarcador; Carcinoma d'ovari serós d'alt grau; Deficiència de recombinació homòloga, The RAD51 test is emerging as a promising biomarker for the assessment of functional homologous recombination deficiency (HRD). Yet, the robustness and reproducibility of the immunofluorescence-based RAD51 test, in different academic laboratories, have not been systematically investigated. Therefore, we tested the performance of the RAD51 assay in formalin-fixed paraffin-embedded (FFPE) high-grade serous ovarian carcinoma (HGSOC) samples in four European laboratories. Here, we confirm that subtle differences in staining procedures result in low variability of RAD51 and γH2AX scores. However, substantial variability in RAD51 scoring was observed in some samples, likely due to complicating technical and biological features, such as high RAD51 signal-to-noise ratio and RAD51 heterogeneity. These results support the need to identify and perform additional quality control steps and/or automating image analysis. Altogether, resolving technical issues should be a priority, as identifying tumours with functional HRD is urgently needed to guide the individual treatment of HGSOC patients. Follow-up studies are needed to define the key tissue quality requirements to assess HRD by RAD51 in FFPE tumour samples, as this test could help in guiding the individual treatment of HGSOC patients., This work was supported by the Dutch Cancer Society (KWF) (grant: 12995 to TB and MV) and by ERA PerMed (grant ERAPERMED2019-215 to VS). VS received funding from Instituto de Salud Carlos III (CPII19/00033). ALG received funding from Asociación Española Contra el Cáncer (AECC) (INVES20095LLOP) and AHR from Generalitat de Catalunya (PERIS SLT017/20/000081).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

  • Serra Elizalde, Violeta
  • Wang, Anderson T.
  • Castroviejo Bermejo, Marta
  • Polanska, Urszula M.
  • Palafox Sánchez, Marta
  • Llop Guevara, Alba
  • Guzman Torres, Marta
  • Rodriguez Ferreiro, Olga
  • Grueso Gragera, Judit
  • Arribas López, Joaquin Vicente
  • Cortés Castan, Javier
  • Cruz Zambrano, Cristina
  • Balmaña Gelpí, Judith
  • Saura Manich, Cristina
  • Herencia Ropero, Andrea
Cáncer de mama y de ovario; Inhibición WEE1, Càncer de mama i d'ovari; Inhibició WEE1, Breast and ovarian cancer; WEE1 inhibition, Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting in restoration of HRR and protection of stalled replication forks. ATR inhibition was highlighted as a unique approach to reverse both aspects of resistance. Recently, however, a PARPi/WEE1 inhibitor (WEE1i) combination demonstrated enhanced antitumor activity associated with the induction of replication stress, suggesting another approach to tackling PARPi resistance. Experimental Design: We analyzed breast and ovarian patient-derived xenoimplant models resistant to PARPi to quantify WEE1i and ATR inhibitor (ATRi) responses as single agents and in combination with PARPi. Biomarker analysis was conducted at the genetic and protein level. Metabolite analysis by mass spectrometry and nucleoside rescue experiments ex vivo were also conducted in patient-derived models. Results: Although WEE1i response was linked to markers of replication stress, including STK11/RB1 and phospho-RPA, ATRi response associated with ATM mutation. When combined with olaparib, WEE1i could be differentiated from the ATRi/olaparib combination, providing distinct therapeutic strategies to overcome PARPi resistance by targeting the replication stress response. Mechanistically, WEE1i sensitivity was associated with shortage of the dNTP pool and a concomitant increase in replication stress. Conclusions: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi., This work was supported by the Spanish Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI17/01080 to V. Serra, PI12/02606 to J. Balmaña); European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española contra el Cáncer (AECC; LABAE16020PORTT), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; 2017 SGR 540), La Marató TV3 (654/C/2019), and ERAPERMED2019–215 to V. Serra. We also acknowledge the GHD-Pink program, the FERO Foundation, and the Orozco Family for supporting this study (to V. Serra). V. Serra was supported by the Miguel Servet Program (ISCIII; CPII19/00033); M. Castroviejo-Bermejo and C. Cruz (AIOC15152806CRUZ) by AECC; A. Herencia-Ropero by Generalitat de Catalunya-PERIS (SLT017/20/000081); M. Palafox by Juan de la Cierva (FJCI-2015–25412); A. Lau by AECC and Generalitat de Catalunya-PERIS (INVES20095LLOP, SLT002/16/00477); A. Gris-Oliver by FI-AGAUR (2015 FI_B 01075). This work was supported by Breast Cancer Research Foundation (BCRF-19–08), Instituto de Salud Carlos III Project Reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (to J. Arribas). The xenograft program in the Caldas laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). The RPPA facility is funded by NCI #CA16672.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

  • Capoluongo, Ettore Domenico
  • Pellegrino, B.
  • Califano, D.
  • Beltrame, L.
  • Serra Elizalde, Violeta
  • Llop Guevara, Alba
  • Scambia, Giovanni
Molecular testing; Ovarian cancer, Proves moleculars; Càncer d'ovaris, Pruebas moleculares; Cáncer de ovarios, Background The detection of homologous recombination deficiency (HRD) can identify patients who are more responsive to platinum and poly ADP ribose polymerase inhibitors (PARPi). MyChoice CDx (Myriad) is the most used HRD test in ovarian cancer (OC). However, some limitations of commercial tests exist, because of the high rate of inconclusive results, costs, and the impossibility of evaluating functional resistance mechanisms. Patients and methods Two academic genomic tests and a functional assay, the RAD51 foci, were evaluated to detect HRD. One hundred patients with high-grade OC enrolled in the MITO16A/MaNGO-OV2 trial and treated with first-line therapy with carboplatin, paclitaxel, and bevacizumab were analyzed. Results The failure rate of the two genomic assays was 2%. The sensitivity in detecting HRD when compared with Myriad was 98.1% and 90.6%, respectively. The agreement rate with Myriad was 0.92 and 0.87, with a Cohen’s κ coefficient corresponding to 0.84 and 0.74, respectively. For the RAD51 foci assay, the failure rate was 30%. When the test was successful, discordant results for deficient and proficient tumors were observed, and additional HRD patients were identified compared to Myriad; sensitivity was 82.9%, agreement rate was 0.65, and Cohen’s κ coefficient was 0.18. The HRD detected by genomic assays and residual tumor at primary surgery and stage was correlated with progression-free survival at multivariate analysis. Conclusions Results suggest the feasibility of academic tests for assessing HRD status that show robust concordance with Myriad and correlation with clinical outcome. The contribution of the functional information related to the RAD51 foci test to the genomic data needs further investigation., This work was supported by funding from the AIRC [grant numbers IG 2016 – ID. 18921 and IG 2021 – ID. 25932 projects – P.I. SP and CO-2018-12367051 (Ministero della Salute) P.I SP]; Ricerca Corrente grant M2/7 from Ministero della Salute to DC, Ricerca Corrente from Ministero della Salute to SP. SM is supported by the Italian Association for Cancer Research [grant number IG-2017 n: IG19997]. MITO16A/MaNGO-OV2 trial was partially supported by Roche. AL is a recipient of a grant from the Asociación Española contra el Cáncer (AECC) [grant number INVES20095LLOP]. VS is a recipient of a grant from the Instituto de Salud Carlos III [grant number CPII19/00033] and a European grant for personalized medicine [grant number ERAPERMED 2019-215]. BP is a recipient of a grant from GOIRC. BP was supported by ESMO with a Clinical Translational Fellowship aid supported by Roche. Any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of ESMO or Roche. NC has received funding from AstraZeneca (to the institution). FP has received funding from Roche, AstraZeneca, Pfizer, Merck Sharp & Dome, Bayer, Incyte, Taiho Oncology, Janssen Cilag, Exelixis, Aileron, and Daiichi Sankyo (grants to the institution for clinical trial activities).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts

  • Òdena, Andreu
  • Casals, Eloi
  • Molina, Cristina
  • Coşkun, Meriç
  • Guzman Torres, Marta
  • Brasó Maristany, Fara
  • García-Galea, Eduardo
  • Herencia Ropero, Andrea
  • Domènech Garcia, Heura
  • Rodríguez, Olga
  • Grueso, Judit
  • Dienstmann, Rodrigo
  • Oliveira, Mafalda
  • Monserrat, Laia
  • Serra, Violeta
Patritumab deruxtecan; Xenografts; Breast cancer, Patritumab deruxtecan; Xenoinjertos; Cáncer de mama, Patritumab deruxtecan; Xenoempelt; Càncer de mama, Novel antibody-drug conjugates (ADCs) have shown potent antitumor activity across multiple cancer types. However, the key determinants of therapeutic response remain under investigation. In this study, we aimed to identify potential determinants of long-term response to patritumab deruxtecan (HER3-DXd; MK-1022), a HER3-directed ADC linked to a potent topoisomerase I inhibitor (TOP1i) payload, using a cohort of thirty-one breast cancer (BC) patient-derived xenograft (PDX) models. Fourteen out of 31 (45%) PDXs exhibited a profound and sustained response to HER3-DXd. Basal-like PAM50 intrinsic subtype, limited prior exposure to chemotherapy and intrinsic sensitivity to the TOP1i irinotecan were associated with long-term response. Additionally, HER3-DXd showed sustained activity in BRCA1/BRCA2-mutated PARPi-resistant PDX models. Long-term responders exhibited persistent DNA damage and lacked early transcriptional activation of the G2/M cell cycle checkpoint that allow for DNA repair and RNA-DNA hybrid (R-loop) resolution, in parallel resulting in immune pathways transcriptional activation. Notably, characteristics linked to long-term response were primarily associated with the TOP1i payload activity., VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA program from the Generalitat de Catalunya for their support on this research. This study was supported by the Asociación Española Cáncer de Mama Metastásico (AECMM) (III Metapremio M. Chiara Giorgetti 2021) and by the Catalan Agency AGAUR-FEDER (2021 SGR 01510 to V. Serra). V. Serra received funds from the Instituto de Salud Carlos III (ISCIII), and co-funded by the European Union (PI20/00892 and CPII19/00033). The FERO Foundation and GHD also provided support to V. Serra. A. Òdena and L. Monserrat received fellowships from the Agency for Management of University and Research Grants (2022 FI_B 00664 and AGAUR 2019 FI_B 01199, respectively). F. Brasó-Maristany received funding from Fundación científica AECC Ayudas Investigador AECC 2021 (INVES21943BRAS) and Fundación Contigo (HIMALAIA). A. Herencia-Ropero received funding from Generalitat de Catalunya (PERIS SLT017/20/000081). F. Pedretti received a fellowship from La Caixa Foundation (ID 100010434) (LCF/BQ/DI19/11730051). H. Domènech received a Severo Ochoa fellowship from the Spanish Ministry of Science and Innovation (PRE2021-099087). A. Esteve-Codina. reports that Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. S. Chandarlapaty is supported by MSK Cancer Center Support Grant P30 CA008748 and the BCRF. A. Prat received funding from the Breast Cancer Research Foundation (BCRF-22-198, BCRF-23-198, BCRF-24-198), Beca Marta Santamaría, Fundación CRIS contra el Cancer (PR_EX_2021-14), Agència de Gestó d’Ajuts Universitaris I de Recerca (2021 SGR 01156), Fundación Fero (ONCOXXI21), Asociación Cáncer de Mama Metastásico (IV Premios M. Chiara Giorgetti), PI22/01017: funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and RESCUER: funded by European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912. We would like to acknowledge Daiichi Sankyo and Merck Inc. for providing the HER3-DXd and the IgG-DXd and Astrazeneca Inc. for supplying the olaparib used in the study. Finally, we would like to acknowledge the patients who donate samples for the generation of the PDX models used in this study.
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

  • Martínez Arranz, Ibón
  • Bruzzone, Chiara
  • Noureddin, Mazen
  • Gil Redondo, Rubén
  • Mincholé, Itziar
  • Bizkarguenaga, Maider
  • Arretxe, Enara
  • Iruarrizaga Lejarreta, Marta
  • Fernández Ramos, David
  • Lopitz Otsoa, Fernando
  • Mayo, Rebeca
  • Embade, Nieves
  • Newberry, Elizabeth
  • Mittendorf, Bettina
  • Izquierdo Sánchez, Laura
  • Smid, Vaclav
  • Arnold, Jorge
  • Iruzubieta, Paula
  • Pérez Castaño, Ylenia
  • Krawczyk, Marcin
  • Marigorta, Urko M.
  • Morrison, Martine C.
  • Kleemann, Robert
  • Martín Duce, Antonio|||0000-0001-8751-9224
  • Hayardeny, Liat
  • Vitek, Libor
  • Bruha, Radan
  • Aller de la Fuente, Rocío
  • Crespo, Javier
  • Romero Gómez, Manuel
  • Banales, Jesús M.
  • Arrese, Marco
  • Cusi, Kenneth
  • Bugianesi, Elisabetta
  • Klein, Samuel
  • Lu, Shelly C.
  • Anstee, Quentin M.
  • Millet, Oscar
  • Davidson, Nicholas O.
  • Alonso, Cristina
  • Mato, José M.
14 p., Background and aims: We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. Approach and results: We analyzed serum metabolome from 1154 individuals with biopsy-proven NAFLD, and from four mouse models of NAFLD with impaired VLDL-triglyceride (TG) secretion, and one with normal VLDL-TG secretion. We identified three metabolic subtypes: A (47%), B (27%), and C (26%). Subtype A phenocopied the metabolome of mice with impaired VLDL-TG secretion; subtype C phenocopied the metabolome of mice with normal VLDL-TG; and subtype B showed an intermediate signature. The percent of patients with NASH and fibrosis was comparable among subtypes, although subtypes B and C exhibited higher liver enzymes. Serum VLDL-TG levels and secretion rate were lower among subtype A compared with subtypes B and C. Subtype A VLDL-TG and VLDL-apolipoprotein B concentrations were independent of steatosis, whereas subtypes B and C showed an association with these parameters. Serum TG, cholesterol, VLDL, small dense LDL5,6 , and remnant lipoprotein cholesterol were lower among subtype A compared with subtypes B and C. The 10-year high risk of CVD, measured with the Framingham risk score, and the frequency of patatin-like phospholipase domain-containing protein 3 NAFLD risk allele were lower in subtype A. Conclusions: Metabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification., National Institutes of Health (USA), Netherlands Organization for Applied Scientific Research (TNO) (Países Bajos), Newcastle NIHR Biomedical Research Center, Czech Ministry of Health, Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (FEDER), Departamento de Industria, Transición Energética y Sostenibilidad (Gobierno Vasco), Fundación La Caixa, Unión Europea, Fondo Nacional de Desarrollo Científico y Tecnológico (Fondecyt) (Chile), Comisión Nacional de Investigación, Ciencia y Tecnología (Chile), Agencia Nacional de Investigación y Desarrollo (ANID) (Chile)